C E L E B R A T E

E D U C A T E

I N N O V A T E

C A S E Y E Y E I N S T I T U T E A N N U A L R E P O R T 2 0 0 2

C A S E Y E Y E I N S T I T U T E A N N U A L R E P O R T 2 0 0 2

Letter from the Chairman page 1

Research To Prevent Blindness page 2

Cornea page 4

Donor Profile: The Pettis page 6

Genetics page 7

Glaucoma page 8

Uveitis and Inflammatory Diseases page 10

Retina/Macular Degeneration page 12

Donor Profile: Bula “Bea” Arveson page 14

Low Vision page 15

Ophthalmic Plastic and Reconstructive Surgery page 16

PediatricsElks Children’s Eye Clinic page 18

Neuro-Ophthalmology page 20

Casey Ophthalmic Associates page 21

Clinical Trials page 22

Honors and Awards page 29

Clinical and Research Faculty page 30

Fellows and Residents page 33

Residency Program page 33

Contributions to the Casey Eye Institute page 34

TABLE OF CONTENTS

The Casey Eye Institute

(CEI) is an academic

regional eye center

dedicated to preventing

blindness through

research, and to

bringing the highest

quality patient care

and advanced technology

to the Pacific Northwest.

1

Dear Friends:

In this, our first annual report, we celebrate our successes and share the good news

of innovation in science and clinical care. We also mark a new era in Casey history: in

2001, we celebrated ten years in our own freestanding institute, and last year we

kicked off a $26 million campaign to expand the building.

Our rapid growth makes it imperative to enlarge our facility. Since we first opened our

doors in 1991, our federal research funding has more than tripled. Funding from the

National Institutes of Health places OHSU in 9th place among all institutes receiving

support from the National Eye Institute. Clinical growth has been extraordinary –

a 100% increase in outpatient visits since 1991 (over 44,000 in 2002). Our staff has

increased to 270 people, most still housed in the original, 120,000-square foot building.

This report highlights many of the accomplishments of our researchers and educators.

Their achievements span a gamut that ranges from unraveling the genetic mysteries

of glaucoma and macular degeneration, the leading causes of visual loss among the

elderly in this country, to advances in online education. There are many numbers that

could be quoted. For example, our uveitis service, a small division in this department,

has seven NIH grants. Our residency training program is more sought-after than ever.

We now have 80 applicants for every available position. But an academic department

is much more than numbers or specific achievements. It is a community which hopefully

provides a unique constellation of resources in a supportive and collaborative environ-

ment that advances our knowledge, cares for the sick and improves our future.

Our greatest accomplishment at Casey is developing the type of community that I just

described. I am particularly proud to report that the Casey spirit is thriving.

It embodies the values of academic medicine that we all cherish. It promises us a

bright future.

I want to conclude this introductory statement with comments about a venture that is a

major source of pride for me. In 1999, we formed a partnership with Legacy’s Devers

Eye Institute on the Good Samaritan campus in northwest Portland, emphasizing

cooperation rather than competition. Together, we can better allocate scarce

resources and benefit the entire region. This affiliation adds to our talent pool and

enriches the residency experience. We share an eye bank and jointly host Grand

Rounds, strengthening our commitment to learning, patient service and the local

community.

2002 was a watershed year in the history of the Casey Eye Institute, one whose promise

will be fulfilled in the years ahead. As you read, I know you will come to share our

sense of excitement at what the future holds.

Sincerely,

Joseph E. Robertson, M.D., M.B.A.

Professor and Chairman

2

Research toPreventBlindness is the

world’s leading organization

in support of eye research.

In 1982, New York-based

RPB selected the Department

of Ophthalmology in the

Oregon Health & Science

University as its seventh

regional eye center, and

played a major role in con-

ceiving and developing the

Casey Eye Institute. This

included mobilizing financial

resources and procuring

essential laboratory space,

equipment and scientific

personnel.

According to RPB chair-

man David Weeks, OHSU

was chosen because its

ophthalmology department

had the talent to attract,

train and inspire

researchers of the highest

caliber. And now, more

than 20 years later, Weeks’

foresight has proven

prophetic: The Casey Eye

Institute has become one

of the leading eye research

facilities in the world.

This interactive relationship

is further evidenced by

ongoing collaboration with

RPB. RPB has awarded the

Casey Eye Institute nearly

$3 million over the years.

According to Joe Robertson,

M.D., chairman of the

Department of Ophthalmology,

“Many of our advances can

be linked directly to our

long-term relationship with

RPB.”

RPB funding, both restrict-

ed and specific grant

awards, has allowed the

department to pursue

research in uveitis, glauco-

ma, macular degeneration,

cataracts, and retinal and

corneal diseases.

RPB ADDS CRITICAL FUNDING

(l to r) David Weeks, Dr. Kenneth Swan andDr. Fritz Fraunfelder during the Casey’s construction.

Winner of the prestigious CareerDevelopment Award from RPB, Justine Smith, M.B.B.S., Ph.D., is studying uveitis. Using new molecularbiology technology known as microarray,she initiated a project designed to showhow Toxoplasma gondii influences thegene expression of cells within the eyeduring toxoplasmic retinochoroiditis.

3

John C. Morrison, M.D., receivedthe Lew Wasserman Award fromRPB, and is studying the cellularresponse of the optic nerve head. His findings have led to a hypothesisthat explains why early damage inhuman glaucoma characteristicallyoccurs in the superior and inferioroptic nerve head.

William D. Mathers, M.D., recipient of the RPB Physician-Scientist Award, investigates the interaction of the surface of the eye and the regulation of tear production in the lacrimal gland.

RPB Senior ScientificInvestigator Ted Acott,

Ph.D., focuses on under-standing how the trabecularmeshwork senses intraocular

pressure changes andresponds to maintain it

within acceptable levels toavoid glaucoma in the

healthy eye. Understandingthe normal functions of this

tissue should provide keysfor correcting the changes,

which result in elevatedintraocular pressure and

trigger optic nerve damagein glaucoma.Mary Wirtz, Ph.D., an RPB Dolly Green

Scholar, is using RPB funding to support several glaucoma genetic projects. By analyzing DNA samples, Wirtz and her team mapped the third and sixth gene of the six now associated with glaucoma.

2002 recipient of the Robert E. McCormickScholar Award, Tim Stout, M.D., is develop-ing ways to genetically modulate the processof intraocular cellular proliferation. This isdone to prevent the blinding complicationsof diseases such as age-related maculardegeneration, proliferative diabeticretinopathy, retinopathy of prematurity, and post-cataract extraction posterior capsular opacification.

Stephen Planck, Ph.D., recipientof the James S. Adams ScholarAward from RPB, is using a multifaceted approach to studyingocular inflammation. His team isculturing cells from the lining ofthe blood vessels and studying theirrole as gatekeepers for the whiteblood cells. Videomicroscopy is usedto track the different kinds of cellsthat initiate and execute immuneand inflammatory responses.

4

CORNEA

Stem cell transplants give the gift of sight.

Cornea service director

Larry F. Rich, M.D. treats

some forms of corneal

disease with epithelial stem

cell transplants. The trans-

plants can help regenerate

cells—and sight—damaged

by disease, adverse drug

reactions, or burns. Dr. Rich

recalls a gift of epithelial

cells from one identical

twin to another that allowed

a woman to regain sight

after 30 years of blindness.

Used as a precursor to

whole-cornea grafts, prolif-

erating stem cells can

sometimes even preclude

the need for a transplant,

and grafts of stem cells

and conjunctival tissue can

keep pterygia from recurring.

Another tool for treating

corneal disease is Casey’s

confocal microscope,

which William Mathers, M.D.

is using to evaluate the

effectiveness of antibiotics

in treating acanthamoeba.

By allowing researchers to

watch cells interact, the

microscope can speed

assessment of whether—

and which—antibiotics

work against disease. We

also use confocal

microscopy in refractive

surgery (to determine the

thickness of LASIK flaps),

to diagnose infectious

disease and to collaborate

on immunologic research

with James T. Rosenbaum,

M.D., director of Casey’s

uveitis service.

Casey Eye Institute’s

cornea service is home to

the National Registry of

Drug-Induced Ocular Side

Effects, the only resource

of its kind in any subspe-

cialty. Founded by F.T.

“Fritz” Fraunfelder, M.D. in

1976, the Registry went

Larry F. Rich, M.D.

Damien Macaluso, M.D.

5

online in 2002 under the

direction of Rick Fraunfelder,

M.D. (www.eyedrugreg-

istry.com). The father-son

team has written extensive-

ly on ocular pharmacology,

recently reviewing side

effects of high-profile drugs

like Gleevec and Zyrtec.

Log on to the Registry to

report cases or request

information on a particular

drug.

Casey is currently the only

site in the country treating

ocular surface tumors with

liquid nitrogen cryotherapy.

At -196°C, tumors are

quickly frozen. “The treat-

ment is less damaging to

the eye than radiation,”

notes Rick Fraunfelder, M.D.,

adding that this high-tech

surgery is also quicker and

more cost-effective than

other methods.

The Casey cornea team

continues working to make

refractive surgery safer

and more successful,

using our substantial

patient database to evalu-

ate and improve outcomes.

In bench research, Dr.

Mathers and Yuan Fang,

M.D., Ph.D. are studying

molecular interactions

between the lacrimal gland

and other organ systems,

working toward a possible

genetic explanation for the

persistent problem of dry

eye. Damien Macaluso,

M.D. is also collaborating

with Tim Stout, M.D. of our

retina service on gene ther-

apy for corneal disease.

To disseminate the insights

gained in the laboratory

and clinic, Macaluso plans

to make the joint Casey/Devers

Eye Institute Grand Rounds

available on the Web.

Special technology will

make lectures easy to

download even without a

high-speed connection,

and a series of questions

at each lecture’s end will

allow viewers to earn CME

credits for virtual atten-

dance. According to

Dr. Macaluso, not only

virtual Grand Rounds but

also Web-based telecon-

ferences are in Casey’s

future.

F.T. “Fritz” Fraunfelder, M.D. Rick Fraunfelder, M.D.

6

Giving Well: The Story of August and Margaret Petti

Owners of the Portland

landmark Henry Thiele’s

Restaurant, August Petti and

his wife Margaret Thiele Petti

sought help at OHSU in the

late 1980s when August’s

eyesight began to fail. The

pair saw Kenneth Swan,

M.D. in early 1990. He

referred them to corneal spe-

cialist Larry Rich, M.D., who

performed a corneal transplant

that allowed the 98-year-old

gentleman to regain his sight

and enjoy life again. Later,

Margaret Petti had cataract

surgery at Casey, and saw

Michael Klein, M.D., and

David Wilson, M.D., for

treatment of her diabetic

retinopathy. Both August and

Margaret Petti were also

patients of F.T. “Fritz”

Fraunfelder, M.D.

Casey Eye Institute’s fourth-

floor atrium, named for the

Pettis, incorporates the

world’s largest glass floor.

Made of brilliant blue glass

blocks, it is a stunning

reminder of this generous

couple.

The Pettis created three

endowments at Casey:

The Chair of Ophthalmology

in honor of Kenneth C.

Swan, M.D., currently held

by Joseph E. Robertson, M.D.

The Chair for the

Director of Corneal Service

in honor of Larry F. Rich,

M.D., who holds the chair.

The Research Fund for

corneal and diabetes-

related diseases.

7

OPHTHALMIC GENETICS CENTER

“We are entering an era of being able to make more precisediagnosis more quickly through testing at the molecular level.”

Richard Weleber, M.D.

The Ophthalmic Genetics Center at

Casey Eye Institute is one of few in

the country devoted to diagnosing

complex genetic diseases with asso-

ciated ophthalmic problems.

Director Richard Weleber, M.D., is

a founding member of the American

Board of Medical Genetics. He

offers a unique set of qualifications

since he is both a board certified

ophthalmologist and medical

geneticist.

Many genetically linked syndromes

include eye problems in their medical

landscape. In the past, making a

specific diagnosis was a difficult and

lengthy process, but that scenario

is changing. As Weleber states,

“We use laboratories across the

country where specialized genetic

tests have been developed,

enabling us to diagnose diseases

previously very difficult to pinpoint.”

Like a master sleuth, Weleber care-

fully assembles all the pieces of the

puzzle. When fitted together, they

often form a picture of a specific

genetic syndrome.

Karmen Trzupek, M.S., assists

Weleber by providing genetic coun-

seling to patients and their families.

“Having a genetic counselor is a

great advantage,” Weleber continues,

“Often, we are able to establish the

presence of an inherited disease

previously unknown in a family.”

Chrystal Smith, who lives in Juneau,

Alaska, is grateful for Weleber’s

expertise. Two years ago, she

began experiencing vision loss and

was diagnosed with retinitis pigmen-

tosa. However, Smith felt she needed

more answers and found Dr. Weleber.

After extensive testing and exploring

her family medical history, Weleber

diagnosed autosomal dominant neo-

vascular inflammatory vitreoretinopathy

(ADNIV). The rare disease had been

traced to one family in Iowa and

Ohio. Smith recalled a paternal

grandfather who had lost vision.

“Looking for more answers, I called

a second cousin who is a Midwest

physician. She explored our family

genealogy and found early family lin-

eage linked to this same family in

Iowa.”

Knowing a specific diagnosis, Smith

will be able to mitigate conditions

associated with this disease, includ-

ing a greater likelihood of cataracts

and glaucoma. She continues,

“I have been so impressed seeing

research in action. Even though the

Casey is two plane flights and two

thousand miles away, every visit is

very much worth the effort.”

Richard G. Weleber, M.D.

8

CEI researchers are working

hard to improve treatment

for this devastating eye

disease, to understand its

causes, and ultimately, to

find a cure.

John Morrison, M.D., and

Elaine Johnson, Ph.D.,

have developed a glaucoma

model that highlights the

focal nature of optic nerve

damage, bringing us

several steps closer to

understanding how elevat-

ed intraocular pressure

causes glaucoma.

Morrison and Johnson

have found a distinct,

repeatable pattern of injury,

allowing them to pinpoint

the injury site in a specific

region of the nerve head.

Morrison’s work was

recently recognized with

the Lew R. Wasserman

Merit Award for Glaucoma

Research from Research to

Prevent Blindness. He is

also the recipient of a four-

year NIH grant, “Studies in

Glaucomatous Optic Nerve

Damage.”

Approaching the problem

from a genetic perspective,

John Samples, M.D., and

Mary Wirtz, Ph.D., have

discovered the third and

sixth (out of six) known

genetic loci for open angle

glaucoma in a study of

several large families. The

third locus, GLC1C, was

the first to be clearly delin-

eated for adult high-pres-

sure, open-angle glaucoma.

This study, derived from

Samples’ practice and

funded by several NEI

grants, was carried on in

both Portland and Greece.

Samples is also working

with other collaborators to

determine whether there is

value in testing glaucoma

genes commercially at

present.

In another approach to

elevated IOP, Samples and

Al Eisner, Ph.D., are using

psychophysical testing to

evaluate the neuroretinal

damage caused by elevated

IOP and drugs (most

GLAUCOMA

John R. Samples, M.D.

Glaucoma model brings closerunderstanding of how elevatedpressure causes glaucoma.

9

recently, tamoxifen). In

addition, Samples is

collaborating with Paul

Knepper, M.D., Ph.D., of

Northwestern University to

study specific molecules,

termed CD44, which are

only elevated in primary

open-angle glaucoma.

These molecules seem to

be highly toxic to the out-

flow structures and to reti-

nal and optic nerve cells,

as well as to the trabecular

meshwork. He also has a

longstanding interest in the

effects of cytokines on the

meshwork’s extracellular

matrix and is examining the

presence of certain

enzymes (interleukin relat-

ed kinases, or IRAK) in the

trabecular meshwork asso-

ciated with reaction to the

cytokines.

As of this writing, the only

selective laser trabeculo-

plasty unit in the state of

Oregon is housed at the

Casey Eye Institute.

Researchers John Bradley,

Ph.D., Ted Acott, Ph.D.,

and Samples are evaluat-

ing it, both in patients and

in the laboratory, with the

goal of further refining the

mechanism by which it

works. In addition,

Samples is working with a

small California company

called Glaukos to develop

an entirely new type of out-

flow device for lowering

IOP. Clinical trials are

planned for mid-2003.

Both Morrison and

Samples continue to make

important contributions to

the literature. Working with

Irvin P. Pollack, M.D., of the

Wilmer Eye Institute,

Morrison has edited a new,

comprehensive text,

Glaucoma: Science and

Practice. This textbook,

released by Thieme

Medical Publishers in

November 2002, contains

contributions from more

than 35 recognized experts

from throughout the world.

It covers basic science,

clinical diagnosis and man-

agement of all forms of

glaucoma, and includes

important new details on

etiology, genetics, and epi-

demiology as well as a dis-

cussion of neuroprotection.

Samples is presently work-

ing on a book on ophthalmic

genetics for W.B. Saunders.

Eisner and Samples are

co-investigators on “Visual

Adaptation Limits of Age-

Related Disease” (the two

also hope to begin an NIH-

funded study this year on

female hormones and

vision.) Samples, who cur-

rently serves on the AAO’s

Technology Assessment

committee as well as the

committee charged with

rewriting the association’s

glaucoma text, is co-direc-

tor of a national glaucoma

symposium to be held in

Las Vegas in mid-2003.

John C. Morrison, M.D.

10

Directed by James T.

Rosenbaum, M.D., holder

of the Edward T.

Rosenbaum Chair in

Inflammatory Diseases, the

service includes co-director

Eric B. Suhler, M.D., chief

of ophthalmology at the

Portland Veterans Affairs

Medical Center; Justine

Smith, M.B.B.S., Ph.D.;

Roger George, M.D., and

Daryl Kurz, M.D.

Rosenbaum is the current

president of the American

Uveitis Society.

The Casey Eye Institute is

an important part of new

uveitis therapy studies.

Patients come from all over

the Pacific Northwest for

specialized care, some-

times including experimental

drugs. For example,

Rosenbaum, Suhler and

Smith are investigating

infliximab (Remicade), a

monoclonal antibody

against tumor-necrosis factor

alpha, for treatment of

vision-threatening, non-

infectious uveitis that is

refractory to other systemic

immunosuppressants.

Though Remicade has

already been proved effec-

tive in the treatment of

other systemic inflammatory

diseases (such as Crohn

disease and rheumatoid

arthritis), this is the first trial

of the drug specifically for

ocular inflammation.

Since 1985 the NIH has

generously supported

OHSU’s basic research into

the pathogenesis of uveitis

and ocular inflammation.

UVEITIS and INFLAMMATORY DISEASES

“Uveitis researchers are looking to the needs of the future.”

James T. Rosenbaum, M.D. with his father, Edward T. Rosenbaum, M.D.

11

CEI researchers, including

Stephen R. Planck, Ph.D.,

were among the first to

study cytokines and adhe-

sion molecules in ocular

inflammation. CEI is also a

world pioneer in using

intravitreal microscopy to

watch cells at work in the

eyes of living rodents and

people, monitoring immune

system activity in and

around individual blood

vessels or cells as a dis-

ease progresses.

CEI researchers led by

Tammy Martin, Ph.D., have

also embarked on a project

to identify the genes that

increase uveitis risk, col-

lecting family histories and

blood for DNA analysis

from patients throughout

the United States, Canada

and Europe. The Casey is

the only center in the world

to publish on the isolation

and characterization of

microvascular endothelial

cells from the iris. The

endothelial cell is a gate-

keeper in inflammation,

and CEI researchers are

characterizing its role in

uveitis as well as in other

diseases, such as diabetic

retinopathy. Finally, we are

also investigating how a

slight change in a protein

called NOD2 results in

Blau syndrome, a rare,

inherited form of uveitis.

CEI’s uveitis researchers

are looking to the needs of

the future, as Rosenbaum

administers a training grant

that supports seven pre-

doctoral graduate students

in eye-related research. In

the past, this program has

convinced several talented

scientists to take up oph-

thalmic research. Faculty

members are also continu-

ing their own education:

Smith returns in July from a

research fellowship with

Yvonne DeKozak, M.D.,

Ph.D., at the Centre de

Recherches Biomedical

des Cordeliers in Paris,

while Suhler will soon com-

plete his master’s in public

health with an emphasis in

epidemiology and

biostatistics.

Uveitis/Inflammatory Diseases research staff

12

MACULAR DEGENERATION TREATMENT POSSIBILITIES EXPAND

“We will now have the opportunity to deliver therapeutic genes directly to a patient’s cells.”

Timothy Stout, M.D., Ph.D.

“Of all the recent research

developments in the realm of

retinal disorders, the most

exciting is in the field of macular

degeneration,” states Joseph

Robertson, M.D., M.B.A., pro-

fessor and chairman of the

department of ophthalmology.

“Five to ten years ago, we had

very limited treatment options.

Today, we are involved in clini-

cal trials exploring multiple

modes of therapy that existed

only in our imaginations until

now. We can now offer hope of

vision stabilization in many of

our patients and the promise of

vision improvement for all

seems close at hand.”

For the first time, researchers

are learning how to treat eye

disease at the cellular level.

Tim Stout, M.D., Ph.D., enthusi-

astically details how last year’s

completion of the Human

Genome Project is impacting

his life as a retina physician

and researcher. “In the past,

I have only had mechanical

tools such as laser or surgery

to repair eye disease damage.

We will now have the opportunity

to deliver therapeutic genes

directly to a patient’s cells.”

Using this master map of the

30,000 genes in the human

body, Casey researchers have

already pinpointed genes

responsible for macular degen-

eration and glaucoma. As

Stout explains, “We know the

development of many serious

eye diseases is influenced by

one or more abnormal genes.

When we locate all the genetic

players in each disease, we

can then look at what goes

wrong inside the cell and work

on altering those chemical

processes at the cellular level,

halting the disease process

before it even gets started.”

Although still in its infancy, the

ability to deliver therapeutic

genes directly to the retina will

expand the spectrum of possi-

ble treatments for age-related

macular degeneration, or AMD.

Nationally, AMD is the leading

Tim Stout, M.D. (r.) with research staff

Michael Klein, M.D. (l.) with Mitch Schain

Andreas Lauer, M.D.

13

cause of irreversible vision loss

in the U.S., currently affecting

1.7 million people over the age

of 65. An increasing aging

population is propelling

researchers at Casey Eye

Institute and other institutions

across the country to try to

understand the causes and

develop effective treatments for

this often-debilitating disease.

A major underlying cause of

macular degeneration is known

to be angiogenesis, the growth

of unwanted new blood vessels.

These can bleed and scar,

damaging light-sensitive cells

and destroying a person’s cen-

tral vision. This same process

occurs in diabetic retinopathy

and retinopathy of prematurity.

Stout continues, “How these

blood vessels grow is a complex

process. Researchers have

isolated 22 different chemicals

encoded in genes responsible

for growing new blood vessels.

We know gene-containing pro-

teins like vascular endothelial

growth factor (VEGF) promote

vascular growth and others like

pigment epithelial derivative

factor (PEDF) inhibit growth. In

a healthy eye, these two factors

remain in balance. In the dis-

eased eye, biological signals

instruct new vessels to grow,

overpowering those that would

typically prevent the process.”

Stout and Michael Klein, M.D.,

are in the early phase of a

multi-center clinical trial spon-

sored by GenVec, a biotech

company developing anti-

angiogenic drugs designed to

deliver medication directly to

the retina by means of an

injection behind the eye.

This approach to treating AMD

is not completely new.

Beginning two years ago,

Klein, director of the Macular

Degeneration Center, began a

study in conjunction with

Eyetech Pharmaceuticals

involving an investigative drug

named Macugen, also

designed to block new blood

vessel growth. An expanded

study is now underway.

In tandem with gene therapy,

researchers are moving closer

to identifying specific genes

responsible for AMD. In the

Genetics of AMD study led by

Klein and Dennis Schultz,

Ph.D., the DNA of more than

100 families affected by the

disease is being analyzed.

Four years ago, Klein and his

team localized the first gene

linked to AMD in several mem-

bers of a large family.

Klein, along with Andreas

Lauer, M.D., is also conducting

a study of the steroid anacor-

tave acetate and its effectiveness

in preventing new blood vessel

growth. It is being compared to

photodynamic therapy, a major

medical breakthrough

approved in the spring of 2000

for the treatment of wet AMD.

Although this approach does

not restore vision lost to AMD,

it can slow the progression of

the disease.

Other types of laser treatment

are also being studied. Klein

and his team are conducting

the Complications of Age-

Related Macular Degeneration

Trial (CAPT) to learn if a specif-

ic laser treatment can prevent

the advanced complications of

AMD and the associated vision

loss.

The most recent faculty addi-

tion to the retina service, Lauer

has immersed himself in

research as a co-investigator in

several studies, including the

Age-Related Eye Disease

Study (AREDS) at Devers Eye

Institute. He also serves as the

residency program coordinator.

Interest in the carotenoids,

lutein and zeaxanthin, pig-

ments found in green, yellow

and orange fruits and vegeta-

bles evolved into two studies.

Klein and his team are con-

ducting the Carotenoid Study,

sponsored by the Foundation

14

Fighting Blindness, to determine

whether consuming large amounts

of carotenoid-containing foods will

possibly decrease the risk of devel-

oping wet AMD. The Carotenoids

in Age-Related Eye Disease Study

(CAREDS), sponsored by NIH as

part of the Kaiser Women’s Health

Initiative, is looking at how environ-

mental factors such as diet, sunlight

exposure and family history may

influence AMD.

David Wilson, M.D. and Robert

Watzke, M.D., are nearing completion

of the NIH-sponsored Collaborative

Ocular Melanoma Study (COMS),

which began in 1987. Wilson is

also the principal investigator and

a writing committee member of the

Submacular Surgery Trial (SST),

which will conclude in September

2003. In conjunction with Oculex,

he is testing a new delivery system

with a self-dissolving pellet implanted

under the conjunctiva designed to

treat cystoid macular edema. In

addition, Wilson recently completed

his thesis for membership in the

American Ophthalmological

Society involving glucose uptake in

the inner retina.

Generosity Advances Macular Degeneration Research

Bula “Bea” BuckArveson’s voice sparkled with

resolve about helping researchers find

a cure for age-related macular degen-

eration, the leading cause of severe

vision loss in people older than 65.

Because she and two siblings had

experienced vision loss from AMD, she

had a personal interest in this disease.

During a 1995 interview, she spoke of

her desire to assist researchers in find-

ing a cure for AMD. “Something has to

be done and I think OHSU researchers

can do it. I want to help make that possible.”

Although Arveson died last year at the

age of 98, she left a clear directive with

a $5 million gift to the OHSU Casey

Eye Institute, establishing the Bula

Buck and Charles C. Arveson

Endowment Fund. This is one of the

largest private gifts ever given to help

fight macular degeneration.

A patient at Casey for more than a

decade, Arveson also served on the

board of its Macular Degeneration

Center. “Her generous gift will allow us

to dramatically accelerate our

research,” said Michael Klein, M.D.,

director of the center and Arveson’s

physician. “The center has already

been instrumental in advances in drug

therapy, genetics research and nutrition

to prevent and treat this disease, but

this kind of transformative gift can lead

to greater things.”

Born in 1902 to a pioneering family in

Idaho Falls, Idaho, she married Charles

Arveson in 1925 and moved to

Portland. Her husband, who died in

1988, spent 35 years as vice president

and western manager of U.S. Epperson

Underwriting Company. Arveson devoted

much of her life to public service, vol-

unteering for organizations such as

Head Start and the Portland Veterans

Affairs Medical Center. In the early

1930s, she was instrumental in getting

the first black woman admitted to the

nursing program at the University of

Oregon Medical School, now the

OHSU School of Medicine.

Bea Arveson spent a lifetime caring for

others. Her generous legacy will continue

to make a huge difference in conquer-

ing AMD, a disease that can greatly

impact a person’s vision and subse-

quently their quality of life. Sigrid

Button, a former administrator of the

Casey Eye Institute recalls Arveson.

“She always had tremendous foresight

and understood this gift would be the

very best investment for her own family

as well as reaching many lives far into

the future.”

Macular DegenerationTreatment (continued)

David Wilson, M.D.

15

The Casey Eye Institute’s

Low Vision Rehabilitation

Clinic provides an invalu-

able service to patients

referred by ophthalmolo-

gists and optometrists in

Oregon and from many

other states. Clinic director

John Boyer, O.D., evalu-

ates patients with low

vision as a supplement to

their medical ophthalmolo-

gy needs. The clinic helps

patients find ways to pur-

sue their interests and

activities despite the need

for vision assistance.

“People tend to scale down

their lives when faced with

vision loss, which can be

devastating,” Boyer notes.

“It is essential to find ways

to help them maintain a

satisfying lifestyle and

activity level.” Something

as simple as proper light-

ing or as complex as the

latest video technology can

help patients return to

work, school or daily activi-

ties. Even more importantly,

low vision rehabilitation

helps people recover the

independence, autonomy

and optimism they may

have lost.

MAKING THE MOST OF LOW VISION

“It is essential to find ways to help (patients) maintain a satisfying lifestyle...”John Boyer, O.D.

16

OPHTHALMIC PLASTIC and RECONSTRUCTIVE SURGERY

“Our research is ultimately all done to benefit our patients.”Roger A. Dailey, M.D.

Our oculoplastics division

continues to lead the way in

both cosmetic and reconstructive

procedures. Roger A. Dailey,

M.D., has developed new tech-

niques in lacrimal surgery

(Instat for hemostasis), ptosis

surgery (transconjunctival fascia

late sling), and orbital surgery

(LeFort I Orbitotomy). He also

recently designed a globe

retractor (now sold by Bausch

& Lomb) used in optic nerve

sheath decompression and

orbital tumor removal.

Currently, he is working with a

company called Ocular

Concepts to produce iris-

enhanced conformers for post-

operative enucleation patients,

with collaborative trials under-

way. In addition, clinically

based research continues to

flourish at CEI. Allergan

Pharmaceuticals is sponsoring

a new clinical trial of Botox, set

to begin in early 2003. “After

all,” notes Dailey, “our research

is ultimately all done to benefit

our patients.” On the academic

side, Dailey is coauthor, with

John Wobig, M.D., of

Oculoplastic Surgery: Face,

Lacrimal System, and Orbit,

expected from Thieme Medical

Publishers in the fall of 2003.

Holder of the Lester T. Jones

Chair of Ophthalmic Facial

Plastic Surgery - the only

endowed chair in oculoplastics

in the country - Dailey is also

preceptor of CEI’s two-year,

ASOPRS-sponsored fellowship

program, which offers training

in all aspects of ophthalmic

plastic and reconstructive sur-

gery. As one of just 28 such

fellowships (only seven west of

the Mississippi), it has been

extremely competitive nation-

wide. Recently, CEI matched

its first choice yet again for the

fellowship beginning in July

2003.

Roger Dailey, M.D. (r.) and fellow, Stan Saulny, M.D.

Lester T. Jones, M.D.

17

John D. Ng, M.D., covers the

trauma, reconstructive and

pediatric portions of CEI’s

Division of Ophthalmic Facial

Plastic Surgery. Because

Casey Eye Institute is the

Pacific Northwest’s eye trauma

center, he serves patients from

Oregon, Washington, Idaho

and northern California. Ng is

currently developing new

orbital implants using Medpor

Bioglass, a porous polyethyl-

ene/silicone blend that has

been shown to promote blood

vessel growth. By stimulating

growth, this new material can

decrease the time necessary to

complete vascularization by

one-third to one-half. Ng also

uses Bioglass to repair orbital

implants.

In pediatric surgery, Ng is

refining his technique for

implantation of a new, self-

expanding orbital and socket

implant, used to treat congenital

hypoplastic eye socket disorder.

He was the first in the country

to implant these devices

(which were developed in

Germany and only recently

FDA-approved), bilaterally and

simultaneously. For Graves dis-

ease, Ng does small incision

orbital decompression, using a

1-cm lateral canthal skin inci-

sion (orbit only). Finally, he is

developing new approaches to

orbital reconstruction using 3-D

stereolithographic technology

to build custom orbital

implants. Using a 3-D model

based on CT imaging of a

patient’s head, Ng can shape a

custom implant from putty that

is then built by the company.

Among his research interests,

Ng is exploring ways to

improve local anesthetic

administration in office-based

oculoplastic surgery and refin-

ing techniques to address ocular

problems in patients with facial

nerve paralysis.

In addition to his clinical inno-

vations, Ng plays an active role

in academic medicine. He is

associate preceptor for

Casey’s ASOPRS fellowship,

helping train the next genera-

tion of oculoplastics specialists.

He is also co-editor and co-

author of the textbook

Evaluation and Treatment

o f Orbital Fractures: A

Multidisciplinary Approach,

to be published by

W.B. Saunders.

John Ng, M.D. and Nancy Campbell, P.A.-C.

18

PEDIATRICS - ELKS CHILDREN’S EYE CLINIC

The Oregon State Elkshave been integral in the success

of the Elks Children’s Eye

Clinic. This special relationship

between the Department of

Ophthalmology and the Elks

dates back to 1949, when

Dr. Kenneth Swan needed an

oximeter for a baby whose

father was an Oregon Elk.

The Elks raised $2000 for the

oximeter, and soon after, their

continued generosity estab-

lished our pediatric clinic.

In the years since, the Elks

have contributed enormously

to eye care at OHSU. They

helped pay for the nation’s first

microscope for ocular surgery,

the Northwest’s first ophthalmic

excimer laser, and Oregon’s

first photokeratoscope for

children. Today, the Oregon

State Elks Association con-

tributes over $500,000 per

year to the Elks Children’s Eye

Clinic and the Oregon School

for the Blind.

Oregon Elks donate thousands

of hours volunteering at the

Casey Eye Institute—assisting

patients, working on projects

for staff, and providing informa-

tion to the public with a smile.

The Elks also funded up-to-date

equipment for the pediatric

ophthalmology exam room at

OHSU’s Doernbecher Children’s

Hospital, which is staffed by

the faculty of the Elks Children’s

Eye Clinic.

From the beginning, it was the

Elks’ critical philanthropic

support that allowed Casey’s

founder Kenneth C. Swan, M.D.,

to recruit top faculty. “They’ve

given us an edge,” notes Earl

Palmer, M.D., head of the Elks

Children’s Eye Clinic. Our

pediatrics service has also

been blessed with significant,

ongoing support from the

Annie E. Casey Foundation,

which has allowed us to

expand our services.

For more than 50 years, the

Elks Children’s Eye Clinic has

conducted cutting-edge eye

research and provided superior

eye care for children in the

Pacific Northwest. Dr. Palmer is

principal investigator and chair

Since Casey opened its doors, the number of children seen hasdoubled and the volume of research has tripled.

19

of the NIH-sponsored, multi-

center trial “Cryotherapy for

Retinopathy of Prematurity”(ROP).

Begun in 1986, this nationwide,

landmark study was designed

to help physicians determine

when and how to treat ROP in

order to save as many chil-

dren’s vision as possible. The

study’s results have revolution-

ized ROP management and

inspired more research.

Today Dr. Palmer serves on the

executive committee for a

multicenter trial that will help

identify infants at high risk for

ROP earlier than in the past.

David T. Wheeler, M.D., is

Oregon’s principal investigator

and Ann U. Stout, M.D., is a

co-investigator in this “early

treatments” study, while

researcher Michael Powers,

M.D., is studying retinal vessel

development in a parallel effort

to better understand ROP.

Our pediatrics faculty partici-

pate in several other clinical

trials, all federally funded by

the National Eye Institute.

Palmer belongs to the data and

safety monitoring committee for

a multicenter consortium, the

Pediatric Eye Diseases

Investigative Group (PEDIG).

Wheeler is an investigator for

this group, working on the now

complete Congenital Esotropia

Observational Study as well as

on several amblyopia studies.

He is also an investigator in the

Infant Aphakia Treatment Study

(IATS), researching the best

way to care for infants younger

than 6 months who develop a

cataract in one eye. He partici-

pates in OHSU’s Human

Investigations Program, one of

only five such programs in the

country designed by the NIH to

stimulate physician leadership

in clinical research.

Since Casey Eye Institute

opened its doors in 1991, the

number of pediatric patients

seen here has doubled, and

the volume of research has

tripled. As a major Pacific

Northwest referral center, the

Elks Children’s Eye Clinic treats

approximately 8,000 children

each year. The four current

faculty- Palmer, Laurie

Christensen, M.D., Stout, and

Wheeler- plan to add one more

member to the department

through a pediatric

fellowship program that will

begin in the near future.

Earl A. Palmer, M.D.

David T. Wheeler, M.D.

20

Robert Egan, M.D., and

W. Thomas Shults, M.D.,

form a critical team of clini-

cian investigators who see

patients with the entire

spectrum of neuro-

ophthalmic disorders.

These include ischemic

optic neuropathy, optic

neuritis, optic atrophy,

stroke, multiple sclerosis,

cranial nerve palsies, brain

tumor, myasthenia gravis,

thyroid eye diseases, psy-

chiatric disorders and

unexplained visual com-

plaints.

Through a dynamic collab-

oration between the neuro-

ophthalmology service, the

Oregon Stroke Center, and

the Dotter Interventional

Institute in the OHSU

School of Medicine,

patients are being evaluated

and treated for acute reti-

nal artery occlusion. A

catheter is inserted into a

blood vessel behind the

patient’s eye, and clot-

busting medication is used

to dissolve clots that have

blocked the blood supply

to the retina.

As in the other subspecialties

at the Casey Eye Institute,

the neuro-ophthalmology

unit actively participates in

several research projects.

Subjects diagnosed with

Leber’s hereditary optic

neuropathy in one eye are

being studied to determine

if treatment with an eye

drop medication will

decrease their risk of

developing this condition in

the other eye.

The relationship between

neuro-ophthalmologic

signs and stroke is also

being investigated, as is

the link between optic

nerve hypoplasia and

epilepsy.

NEURO-OPHTHALMOLOGY

Our team sees patients with the entire spectrum of neuro-ophthalmic disorders.

Robert Egan, M.D.

21

CASEY OPHTHALMIC ASSOCIATES

Physicians Bring Diverse Backgrounds to Patient Care

Casey Ophthalmic Associates

cares for a wide-ranging popula-

tion as the general ophthalmology

service at the Casey Eye Institute.

The staff includes Kelly Chung,

M.D., William Farr, M.D., and Devin

Gattey, M.D., who recently joined

the group to accommodate grow-

ing numbers of patients. Tammie

Krisciunas, O.D., specializes in

contact lens care. With the assis-

tance of the OHSU Translation &

Interpreter Services, care is provid-

ed to patients speaking some 40

different languages.

Chung blends a busy clinical and

surgical practice with her interest

in medical informatics, the science

of developing and using informa-

tion technologies to improve health

care. Nationally, she is one of two

ophthalmologists working in con-

junction with the American Academy

of Ophthalmology on the Systematized

Nomenclature of Medical Reference

Terminology (SNOMED) project.

This collaborative endeavor

between the United Kingdom and

the United States is producing a

comprehensive medical terminolo-

gy database to be used worldwide

as the basis for all medical software.

As Chung states, “This terminology

is much different than say, ICD or

CPT, because it is modeled using

artificial intelligence, so information

searches are very robust. For

instance, a search for all patients

with open angle glaucoma would

retrieve not only patients with

“POAG,” but also pigmentary glau-

coma, low tension glaucoma and

pseudo-exfoliation glaucoma with-

out the user specifying or knowing

that these conditions are types of

open angle glaucomas. That knowl-

edge is built into the system.” Also,

since SNOMED has been translat-

ed into several languages, it will

truly give physicians a common

medical language.

Kelly Chung, M.D.

Devin Gattey, M.D., recently joined

Casey Ophthalmic Associates.

Having served in the Peace Corps

in Nepal, his interests gravitate

toward international medicine.

During his inaugural medical mis-

sion, he accompanied a team to

Peru, performing cataract

surgery on native Indians living at

an elevation of over 14,000 feet. In

May of this year, Gattey will journey

to Guatemala as part of another

medical team. “My long term goal is

to establish an international clinic

where Casey providers can have

this kind of experience. Despite

the monumental task of putting a

team together, it is a life-changing

experience.”

Devin Gattey, M.D.

22C

LIN

IC

AL

T

RIA

LS

a

nd

S

TU

DIE

S

Clinical trialsare used todeterminewhether newdrugs or treatmentsare safe andeffective.The followingstudies arecurrentlyunderway atthe Caseyand DeversEye Institutes.

NE-91: Hyperopia and Hyperopic Astigmatism (H-LASIK) with theNidek EC-5000 Excimer Laser SystemPrincipal Investigator: Larry Rich, M.D.Sponsor: NidekPurpose: To compare the safety and predictability of PhotoRefractive Keratectomy (PRK),PhotoAstigmatic Refractive Keratectomy (PARK), Laser in Situ Keratomileusis (LASIK), andAstigmatic Laser in Situ Keratomileusis (A-LASIK) excimer laser methods in reducing nearsightedness and nearsightedness with astigmatism.

Excision and Cryotherapy for PterygiaPrincipal Investigator: Rick Fraunfelder, M.D.Purpose: To study the recurrence rate of pterygia treated with excision and cryotherapy.

Clinical Study to Evaluate the Effectiveness and Safety of OralMemantine in Patients with Chronic Open-Angle GlaucomaPrincipal Investigator: John Samples, M.D. (Casey Eye Institute)Sponsor: AllerganPrincipal Investigator: Steven Mansberger, M.D., M.P.H. (Devers Eye Institute)Purpose: To investigate the safety and efficacy of memantine supplied in tablets for the treat-ment of certain types of open angle glaucoma. The study drug has been sold in Europe fortreatment of dementia syndrome and spastic disorders, such as Parkinson’s disease, and is notyet marketed in any country for use in glaucoma.

Chronology of Functional DeficitsPrincipal Investigator: Brad Fortune, O.D., Ph.D. Sponsor: Legacy Research Advisory CouncilPurpose: This study considers the hypothesis that a generalized retinal neurodegenerationinvolving glial cells and metabolic dysfunction exists in glaucoma.

Memantine Visual Field Reading CenterPrincipal Investigators: G.A. Cioffi, M.D. and C.A. Johnson, Ph.D. Sponsor: Allergan Purpose: To receive, analyze and interpret visual field data collected from worldwide study sitesand perform statistical analysis of data transferred from such sites.

Anterior Chamber to Schlemn’s Canal Shunts in the SurgicalTreatment of GlaucomaPrincipal Investigator: John R. Samples, M.D.Sponsor: Glaukos CorporationPurpose: A new device which shunts aqueous directly from the anterior chamber to Schlemm’scanal is being studied and appears to have some promise in lowering intraocular pressurewithout surgical complications.

CORNEA

GLAUCOMA

23

Genetic Studies of Glaucoma PatientsPrincipal Investigators: Mary Wirtz, Ph.D. Sponsor: National Eye InstitutePurpose: To study the genetics of families with five or more affected individuals with primary open angle glaucoma,drusen of the optic nerve, congenital glaucoma, and selected other secondary glaucomas.

Aquaflow™ Collagen Glaucoma Drainage Device Principal Investigator: John R. Samples, M.D. Sponsor: Staar SurgicalPurpose: To assess the efficacy and safety of the Aquaflow™ Collagen Glaucoma Drainage Device compared to existing surgical methods of draining fluid from inside the eye, such as trabeculectomy. The Aquaflow device is madefrom collagen derived from pigs, and is designed to be inserted into the outer tissues of the eye (sclera).

Evaluation of Multifocal Electroretinogram (MERG) for Use in GlaucomaPrincipal Investigators: Brad Fortune, O.D., Ph.D., G.A. Cioffi, M.D. Sponsor: Murdock TrustPurpose: To evaluate and optimize a new diagnostic procedure known as Multifocal Electroretinography (MERG).MERG will be compared to standard diagnostic procedures as well as to other new, highly sensitive diagnostic instru-ments for detection of early vision damage caused by glaucoma.

Intraocular Hypertension: A Multi-Center, Open Label Study to Determine if Anti-Glaucoma Eye Drop Medicines Prevent or Delay Onset of Glaucoma in Patientswith Intraocular HypertensionPrincipal Investigator: George Cioffi, M.D.Purpose: To determine whether lowering high eye pressure with eye drop medication prevents or delays glaucoma inpatients with increased eye pressure.

Short Wavelength Automated Perimetry in the OHTS TrialPrincipal Investigator: C.A. Johnson, Ph.D. Sponsor: National Eye Institute Purpose: To determine the effects of intraocular pressure lowering treatment versus no treatment on SWAP deficits inocular hypertension patients.

OHTS Visual Field Reading CenterPrincipal Investigator: C.A. Johnson, Ph.D.Sponsor: National Eye Institute Purpose: To process visual field data for the OHTS trial

Objective Perimetry in Glaucoma: Objective Perimetry Evoked ResponseAnalysis (OPERA)Principal Investigator: Brad Fortune, O.D., Ph.D.Purpose: To evaluate a new visual screening device that may provide earlier detection and better monitoring of glaucoma.

Perimetry and Psychophysics in GlaucomaPrincipal Investigator: Chris A. Johnson, Ph.D.Purpose: To evaluate several new test procedures that are believed to detect the earliest changes produced byglaucoma.

CL

IN

IC

AL

T

RIA

LS

a

nd

S

TU

DIE

S24

Genetics of Age-Related Macular DegenerationPrincipal Investigator: Michael Klein, M.D.Sponsor: National Eye InstitutePurpose: To find the genes that cause age-related macular degeneration. Identifying these disease-causing genes willlead us directly to the cause of the disease.

Nutrition and Age-Related Macular DegenerationPrincipal Investigator: Michael Klein, M.D.Sponsor: Casey Eye Institute/Clinical Nutrition, OHSU/Tufts University Center of AgingPurpose: To find out if increasing amounts of foods containing carotenoids, lutein and zeaxanthin will increase the levelof pigment in the macula and protect against macular degenerative changes.

Evaluation of Intravitreal Injections of EYE 001 (Anti-VEGF Aptamer) in Patientswith Exudative Age-Related Macular Degeneration (AMD)Principal Investigator: Michael Klein, M.D.Sponsor: Eyetech PharmaceuticalsPurpose: To establish the safety and efficacy of intravitreal injections of EYE001 given in 6 week intervals.

Evaluation of Anecortave Acetate versus Visudyne in Patients with SubfovealExudative Age-Related Macular Degeneration (AMD) Principal Investigator: Michael Klein, M.D.Sponsor: AlconPurpose: To evaluate the safety and effectiveness of anecortave acetate in preventing the growth of blood vesselsunder the retina in subjects with AMD as compared to treatment with PDT and Visudyne.

A Study of ADGVPEDF.11D in Neovascular Age-Related Macular Degeneration (AMD) Principal Investigators: Michael Klein, M.D. and Timothy Stout, M.D., Ph.D.Sponsor: GenVec, Inc.Purpose: To evaluate the safety and effectiveness of this gene therapy medication in slowing the growth of the bloodvessels or improving vision.

Submacular Surgery Trials (SST)Principal Investigator: David Wilson, M.D.Sponsor: National Eye InstitutePurpose: To determine whether surgical removal of subfoveal choroidal neovascularization (CNV) and associated hem-orrhage in patients with age-related macular degeneration (AMD), the ocular histoplasmosis syndrome (OHS), or idio-pathic CNV stabilizes or improves vision more often than observation.

Complications of Age-Related Macular Degeneration (CAPT)Principal Investigator: Michael Klein, M.D.Sponsor: National Eye InstitutePurpose: To determine whether application of low-intensity laser treatment of eyes with drusen in the macula can prevent later complications of age-related macular degeneration and thereby preserve visual function.

MACULA and RETINA

25

AREDS: Age-Related Eye Diseases StudyPrincipal Investigator: Michael Klein, M.D.Sponsor: National Eye InstitutePurpose: To assess the clinical course, prognosis, and risk factors of age-related macular degeneration (AMD) andcataract; to evaluate the effects of antioxidants and zinc on the progression of AMD and antioxidants on the development and progression of lens opacities.

CAREDS: Carotenoids in Age-Related Eye DiseasePrincipal Investigator: Michael Klein, M.D.Sponsor: NIH Kaiser Permanente Women’s Health Initiative Purpose: To look at environmental factors (diet, dietary supplements, sunlight exposure, family history) and their role inage-related eye disease.

Oculex Pharmaceutical Study of Macular EdemaPrincipal Investigator: David Wilson, M.D.Sponsor: Oculex PharmaceuticalsPurpose: To determine the efficacy of a new dexamethasone implant delivery system in the treatment of persistentmacular edema associated with diabetic retinopathy, uveitis, retinal vein occlusion or Irvine Gass syndrome. This clini-cal research study evaluates the safety and effectiveness of an investigational medication to treat macular edema thatpersists despite current treatment methods.

Optical Coherence Tomography in Diabetic Macular EdemaPrincipal Investigator: Robert Watzke, M.D.Purpose: To determine the value of optical coherence tomography (OCT) in the clinical assessment of diabetic macu-lar edema.

Clinical, Electrophysiological, and Molecular Evaluation of Retinitis Pigmentosaand Allied DisordersPrincipal Investigator: Richard Weleber, M.D.Sponsor: Foundation Fighting BlindnessPurpose: To evaluate patients with retinitis pigmentosa and allied disorders, provide genetic counseling, and performDNA candidate gene screening to search for a molecular basis for these diseases.

Multifocal Electroretinographic Values of the Normal EyePrincipal Investigator: Robert Watzke, M.D.Purpose: To perform multifocal electroretinographic testing on human eyes to test the electrical response of groups ofretinal nerve cells in the posterior pole. This is a new method of testing, and this study proposes to establish a stan-dard of normal values in patients with normal eyes, older patients, and those with refractive errors.

Long-Term Sequellae in Parafoveal TelangiectasiaPrincipal Investigator: Robert Watzke, M.D.Purpose: Parafoveal telangiectasia (PFT) is an ocular vascular disease characterized by abnormal retinal vessels. Thepurpose of this study is to determine the long-term results of untreated PFT and its effect on vision. A secondary goalis to determine whether it is associated with existing systemic disease, particularly diabetes.

CL

IN

IC

AL

T

RIA

LS

a

nd

S

TU

DIE

S26

Multi-Center Study of the Safety and Efficacy of Brimonidine-Purite 0.15%Ophthalmic Solution Administered to Patients with Leber’s Hereditary OpticNeuropathyPrincipal Investigator: Robert Egan, M.D.Sponsor: AllerganPurpose: Leber’s hereditary optic neuropathy causes severe and permanent visual loss. To date, no effective treat-ment has been identified. This study hypothesizes that brimonidine purite 0.15% is effective in reducing visual acuityloss.

Retinal Emboli in Acute Ischemic StrokePrincipal Investigator: Robert Egan, M.D.Purpose: To determine the significance of emboli in the eyes to help determine the cause of the stroke.

Optic Nerve Hypoplasia and EpilepsyPrincipal Investigator: Robert Egan, M.D.Purpose: To determine whether patients with seizures or epilepsy have an increased incidence of optic nerve hypoplasia.

Collaborative Ocular Melanoma Study (COMS) Principal Investigator: David Wilson, M.D.Sponsor: National Eye Institute Purpose: 1) To evaluate therapeutic interventions for patients who have choroidal melanoma, and to assess the poten-tial life-preserving as well as sight-preserving role of radiation therapy. 2) To determine which of two standard treat-ments, removal of the eye or brachytherapy, is more likely to prolong survival of eligible patients with medium-sizedchoroidal melanoma. 3) To determine whether preoperative radiation prolongs life for patients whose eyes with largechoroidal melanoma are enucleated.

Breast Cancer and VisionPrincipal Investigator: Al Eisner, Ph.D.Sponsor: Oregon Cancer InstitutePurpose: To assess how the drug, tamoxifen, affects the visual system. The protocol consists of experimental tests ofvisual sensitivity plus conventional ophthalmologic assessment.

Decreased Tumor Recurrence after Excision and Cryotherapy for Suface Eye MalignanciesPrincipal Investigator: Rick Fraunfelder, M.D.Sponsor: Collins Medical TrustPurpose: To perform excision and cryotherapy on surface eye tumors and analyze results of tumor recurrence, visualmorbidity, tumor metastasis, and patient mortality. This research will serve as a basis for future studies into treatmentand prognosis of surface eye tumors.

NEURO-OPHTHALMOLOGY

ONCOLOGY

27

Outcome Study of Cryotherapy and Retinopathy of Prematurity Principal Investigator and National Chairman: Earl A. Palmer, M.D.Sponsor: National Institutes of Health/National Eye InstitutePurpose: Originally launched in 1985 to determine the safety and efficacy of trans-scleral cryotherapy of the peripheralretina in certain low-weight infants with retinopathy of prematurity (ROP) for reducing blindness from ROP. Outcomestudy is to determine the long-term outcome for eyes that had severe (“threshold”) ROP, both with and without cryotherapy.

Early Treatment for Retinopathy of Prematurity Study (ETROP)Principal Investigator: David Wheeler, M.D.Sponsor: National Eye InstitutePurpose: To test the hypothesis that earlier treatment in carefully selected cases will result in an overall better visualoutcome than treatment at the conventional CRYO-ROP threshold point in the disease. “Early” treatment means the eyeis treated before the disease becomes severe.

Follow-up Study of the Early Treatment of Retinopathy of PrematurityTrial (ETROP) Principal Investigator: David Wheeler, M.D.Sponsor: National Eye InstitutePurpose: Because the vision in babies and young children changes significantly, it is believed that there may be long-term differences between the earlier treated eyes and the eyes treated after ROP became severe. This study will followthe vision of the children who were in the original ETROP study up to age 6.

Infant Aphakia Treatment Study (IATS)Principal Investigator: David Wheeler, M.D.Sponsor:: Emory UniversityPurpose: This is a pilot study which explores intraocular lens implantation in infants with monocular cataracts. Thepurpose of this project is to find out which treatment will result in better vision for babies who are born with a cataract inone eye: babies who have the cataract removed to the vision of babies who have the cataract removed and have anintraocular lens put in.

Amblyopia Treatment Studies (ATS)Principal Investigator: David Wheeler, M.D.Sponsor: National Eye Institute

Amblyopia Treatment Study 1Purpose: To determine whether the success rate with drug treatment (atropine) of amblyopia is equivalent to the suc-cess rate with occlusion (patching) therapy; to develop more precise estimates of the success rates of amblyopia treat-ment; to identify factors that may be associated with successful treatment of amblyopia; and to collect data on thecourse of treated amblyopia to provide more precise estimates of treatment effects than are now available

Amblyopia Treatment Study 2: An Evaluation of Patching Regimens for AmblyopiaPurpose: ATS 2 evaluates patching regimens for amblyopia. The treatment of choice for amblyopia is patching thegood eye. However, we do not know how many hours per day the patch should be worn for the best results.Depending on the severity of the amblyopia, the patch will be worn either all day or for 6 hours per day.

PEDIATRICS

CL

IN

IC

AL

T

RIA

LS

a

nd

S

TU

DIE

S28

Amblyopia Treatment Study 3: Evaluation of Treatment of Amblyopia in 7 to < 18 yr olds Purpose: ATS3 assesses the effectiveness of amblyopia treatment in 7 to <18 year olds. If amblyopia is treated by thetime a child is 6 years old, vision usually improves. In older children, we do not know how often improvement canoccur with treatment, and we do not know the best treatment to prescribe. This study explores whether treatment withpatching plus an activity to force the child to use his or her weak eye will improve the child’s vision.

Amblyopia Treatment Study 4: A Randomized Trial Comparing Daily AtropineVersus Weekend Atropine for Moderate Amblyopia Purpose: The primary objective of this study is to compare the visual acuity outcome in the amblyopic eye after 17weeks of daily use of atropine versus weekend only use of atropine.

Genetics of Uveitis StudyPrincipal Investigator: Tammy Martin, Ph.D.Sponsor: National Eye InstitutePurpose: To search for genes or genetic factors that contribute to the development of acute anterior uveitis (or iritis).Many patients with uveitis have family members that also have uveitis. Our ultimate goal is to be able to treat or evenprevent uveitis by better understanding the genetics of this disease.

Use of Remicade in the Management of Vision-Threatening UveitisPrincipal Investigator: James Rosenbaum, M.D.Sponsor: Centocor, Inc.Purpose: To test the hypothesis that inhibition of binding between tumor necrosis factor alpha and its receptors usinginfliximib (Remicade®) is clinically useful in patients with uveitis that is refractory to other forms of systemic immunosup-pressive therapy. Infliximab is given by infusion every 2 months after a loading schedule. It is well tolerated. Recently,the increased risk of infection has been publicized.

Intravitreal Fluocinolone Acetonide Implant in Patients with Non Infectious UveitisPrincipal Investigator: James Rosenbaum, M.D.Sponsor: Bausch & Lomb PharmaceuticalsPurpose: To evaluate the safety and efficacy of intravitreal fluocinolone acetonde implants in the management ofpatients with non infectious uveitis affecting the posterior segment of the eye. This study also compares the safety andefficacy of 2 doses of fluocinolone acetonide delivered by an intraocular/intravitreal implant in patients with non infec-tious uveitis affecting the posterior segment of the eye. This trial involves implantation of a device which slowly releasescorticosteroid over a period of 3 years.

PEDIATRICS (continued)

UVEITIS/INFLAMMATORY DISEASES

29

H O N O R S A N D AWA R D S

Elizabeth Cottle, C.P.C., Casey Eye Institute’scoding and compliance officer, received the PinnacleAward (large practice division) from the AmericanSociety of Ophthalmic Administrators, the administra-tive branch of the American Society of Cataract &Refractive Surgeons (ASCRS). The award was present-ed at the ASCRS-ASOA meeting in June 2002.

Roger A. Dailey, M.D., holds the Lester T.Jones Chair in Ophthalmic Facial Plastic Surgery, theonly endowed chair in the country in this subspecialty.

Frederick T. “Fritz” Fraunfelder, M.D.,former CEI chair, was recently named to the ScientificAdvisory Panel of Research to Prevent Blindness. Healso received the International Society of OcularToxicology’s Scientific Award at its 2002 meeting inLindau, Germany.

Rachael Garrett, O.D., was named YoungOptometrist of the Year for 2002 by the OregonOptometric Physicians Association. She was also presi-dent of the Portland Metropolitan Optometric Society in2001-02.

William Mathers, M.D., was recently honoredwith the Physician-Scientist Award from Research toPrevent Blindness.

John C. Morrison, M.D., won the Lew R.Wasserman Merit Award for Glaucoma Research fromResearch to Prevent Blindness.

John D. Ng, M.D., received an AchievementAward from the American Academy of Ophthalmology.

Earl A. Palmer, M.D., was named to Who’sWho in America for 1999-2002 and Who’s Who in theWest for 2001-02. He was listed as one of “America’sTop Doctors” in 2001 and one of the “Best Doctors inAmerica” in 2002.

Larry F. Rich, M.D., holds the August Petti andMargaret Thiele Petti Chair for the Director of CornealService. This chair was created in his honor.

CEI director Joseph E. Robertson, M.D., M.B.A.,holds the August Petti and Margaret Thiele Petti Chairof Ophthalmology, created in honor of Kenneth C.Swan, M.D. He received the 2002 Dean’s Award fromthe OHSU School of Medicine.

James T. Rosenbaum, M.D., holds theEdward E. Rosenbaum Chair in Inflammation Research.Elected president of the American Uveitis Society, healso received a Discovery Award from the MedicalResearch Foundation and won a Faculty Excellence inEducation Award from the OHSU School of Medicine in2002.

Justine Smith, M.D., Ph.D., received aCareer Development Award from Research to PreventBlindness.

J. Timothy Stout, M.D., Associate Professorof Ophthalmology, is the recipient of a McCormickScholar Award from Research to Prevent Blindness. Healso won the Casey Eye Institute Resident TeachingAward in 2002.

Richard G. Weleber, M.D., received a 1.5million grant from the Foundation Fighting Blindness tobenefit the Oregon Retinal Degeneration Center. He isvice president for the Americas of the InternationalSociety for Clinical Electrophysiology. In 2002, he deliv-ered the Franceschetti Lecture at the InternationalSociety for Genetic Eye Disease (published in theJournal of Ophthalmic Genetics).

Mary Wirtz, Ph.D., discovered (with JohnSamples, M.D.) the sites for two of the six known genesfor primary open-angle glaucoma, evaluating themboth in Portland and in Greece.

30

C L I N I C A L a n d R E S E A R C H FA C U LT Y

Cornea and External DiseaseFrederick T. (Fritz) Fraunfelder, M.D.Professor of Ophthalmology Interests: Anterior segment disease, ocular cancer,ocular pharmacology and toxicology.

Frederick W. (Rick) Fraunfelder, M.D.Assistant Professor of OphthalmologyInterests: Cornea and external disease, anterior segment oncology, cataract and refractive surgery,corneal transplantation, anterior segment reconstruction.

Rachael L. Garrett, O.D.InstructorInterests: Pre- and postoperative refractive surgeryevaluation.

Damien Macaluso, M.D.Assistant Professor of Ophthalmology Interests: Cornea and external disease, refractive surgery, corneal transplantation, complicated cataractand anterior segment surgery.

William D. Mathers, M.D.Professor of Ophthalmology Interests: Corneal transplantation, refractive surgery,corneal diseases, tear film abnormalities, dry eye, confocal microscopic detection of corneal infections.

Larry F. Rich, M.D.Professor of OphthalmologyInterests: Refractive surgery, corneal transplantation,treatment of corneal diseases.

General OphthalmologyKelly D. Chung, M.D.Assistant Professor of Ophthalmology Interests: Cataract/IOL surgery, medical informatics,education for primary care providers and residents.

William F. Farr, M.D.Clinical Associate Professor of Ophthalmology Interests: Comprehensive ophthalmology, aviation medicine.

Devin M. Gattey, M.D.Assistant Professor of OphthalmologyInterests: Comprehensive and hospital-based ophthalmology, cataract and IOL surgery, internationalophthalmology.

Tammie Krisciunas, O.D., M.Ed.Instructor Interests: Contact lenses.

Kenneth C. Swan, M.D.Professor Emeritus of Ophthalmology Interests: Comprehensive ophthalmology.

GlaucomaTed S. Acott, Ph.D.Professor of Ophthalmology, Biochemistry & Molecular Biology Interests: Understanding the molecular causes of primary open-angle glaucoma and the molecularmechanism of laser trabeculoplasty.

Elaine C. Johnson, Ph.D.Assistant Professor of OphthalmologyInterests: Developing physiologically relevant humanglaucoma models. Discovering mechanisms of glaucomatous neuropathy and testing potentially neuroprotective therapies.

Mary Kelley, Ph.D.Assistant Professor of OphthalmologyInterests: Primary open angle glaucoma.

John C. Morrison, M.D.Professor of OphthalmologyInterests: Evaluation and treatment of difficult glauco-mas, glaucoma and cataract surgery, understandingthe mechanism of glaucomatous optic nerve damage.

31

John R. Samples, M.D. Professor of Ophthalmology Interests: Glaucoma diagnosis and therapeutics, pediatric glaucoma, use of anti-metabolites, setonsand combined cataract and glaucoma surgery. Cellbiology of the eye, particularly trabecular meshwork.Facial movement disorders.

Mary K. Wirtz, Ph.D.Associate Professor of Ophthalmology, Molecular andMedical Genetics Interests: Identifying genes involved in the pathogene-sis of glaucoma.

Uveitis and InflammatoryDiseases

Tammy Martin, Ph.D.Research Assistant Professor of Ophthalmology Interests: Analysis of genetic susceptibility to anterioruveitis.

Stephen Planck, Ph.D.Research Associate Professor of Ophthalmology, Cell &Developmental Biology, and MedicineInterests: Intercellular regulation of ocular inflammationand injury responses.

James T. Rosenbaum, M.D.Professor of Ophthalmology, Medicine and Cell Biology Interests: Ocular inflammatory disease, uveitis, scleritis,orbital pseudotumor, ocular cicatrical pemphigoid, sys-temic inflammatory diseases with ocular manifestations.

Justine R. Smith, M.B.B.S., Ph.D.Assistant Professor of Ophthalmology Interests: Mechanisms of uveitis and related diseases,and the design and testing of therapies that specificallyinhibit these mechanisms.

Eric B. Suhler, M.D.Assistant Professor of Ophthalmology Interests: Uveitis and ocular inflammatory diseases,evidence-based ophthalmology, and the eye in systemic disease.

Low VisionJohn M. Boyer, O.D.Assistant Professor of Ophthalmology Interests: Low vision, vision impairment, vision rehabilitation.

Neuro-OphthalmologyRobert A. Egan, M.D.

Assistant Professor of Ophthalmology and Neurology Interests: Neuro-ophthalmology, stroke, ocular motordisturbances, ischemic optic neuropathy, pseudotumorcerebri, optic neuritis.

William T. Shults, M.D.Clinical Professor of Ophthalmology and Neurology Interests: Neuro-ophthalmology, optic neuritis, andother optic nerve diseases.

Ophthalmic Plastic andReconstructive Surgery

Roger A. Dailey, M.D.Associate Professor of Ophthalmology Interests: Cosmetic and reconstructive surgery, lacrimalsurgery, endoscopic and laser surgery, orbital surgery.

John D. Ng, M.D.Assistant Professor of Ophthalmology Interests: Reconstructive eyelid surgery, lacrimal sur-gery, orbital and facial trauma, facial nerve palsy reha-bilitation, orbital reconstruction.

Pediatric Ophthalmology andStrabismus

(Elks Children’s Eye Clinic)Laurie E. Christensen, M.D.Assistant Professor of Ophthalmology and Pediatrics Interests: Strabismus, diplopia and ocular motility disor-ders (children and adults), ocular torticollis, retinoblas-toma, general pediatric vision care.

32

C L I N I C A L a n d R E S E A R C H FA C U LT Y

Pediatric Ophthalmology andStrabismus

(Elks Children’s Eye Clinic)continued

Earl A. Palmer, M.D., F.A.A.P.Professor of Ophthalmology and Pediatrics Interests: Strabismus, diplopia and ocular motility disorders of adults and children. Ocular torticollis, ocular sequelae of premature birth, general pediatricvision evaluation and care.

Ann U. Stout, M.D.Assistant Professor of Ophthalmology Interests: Strabismus and ocular motility disorders ofadults and children, pediatric glaucoma, pediatriccataracts, general pediatric vision evaluation and care.

David T. Wheeler, M.D.Associate Professor of Ophthalmology Interests: Pediatric cataract removal and lens implantation,pediatric glaucoma, strabismus in children and adults,pediatric ocular trauma, pediatric tearing, general pediatric vision evaluation and care.

Retina and Vitreous DiseaseAlvin Eisner, Ph.D.Associate Professor of Ophthalmology and BehavioralNeuroscience Interests: Visual psychophysical techniques.

Michael L. Klein, M.D.Professor of Ophthalmology Interests: Macular degeneration, diabetic retinopathy,macular and retinal vascular diseases.

Andreas Lauer, M.D.Assistant Professor of Ophthalmology Interests: Vitreoretinal disease and surgery, ocular trauma and ocular trauma surgery, macular degeneration.

Joseph E. Robertson, M.D., M.B.A.Professor and Chair of Ophthalmology Interests: Macular surgery, ultrasound, trauma,retinopathy of prematurity, surgical diseases of the reti-na and vitreous.

Dennis W. Schultz, Ph.D.Research Assistant Professor of Ophthalmology Interests: Macular degeneration research.

J. Timothy Stout, M.D., Ph.D.Associate Professor of Ophthalmology Interests: Pediatric vitreoretinal disease and surgery,ocular gene therapy, ocular trauma, macular surgery.

Robert C. Watzke, M.D.Professor of Ophthalmology Interests: Research and treatment of diseases of theretina and vitreous.

David J. Wilson, M.D.Professor of Ophthalmology Interests: Ocular oncology, macular degeneration, oph-thalmic pathology, retinal and vitreous surgery, oculartrauma and ocular trauma surgery.

Retinal Dystrophies andOphthalmic Genetics

Richard G. Weleber, M.D.Professor of OphthalmologyInterests:Ophthalmic genetic disease, retinitis pigmen-tosa, retinal dystrophies and degenerations, syndromeswith retinal degeneration, juvenile or early adult-onsetmacular dystrophies.

33

FFEELLLLOOWWSSDaryl Kurz, M.D.Uveitis and ocular immunology

Raghu C. Murthy, M.D.Vitreoretinal disease and surgery

Stanley M. Saulny, M.D.Ophthalmic plastic and reconstructive surgery

Jonathan Yoken, M.D.Vitreoretinal disease and surgery

RREESSIIDDEENNTTSSFirst-Year (2002-2005)

Dustin Heringer, M.D.University of North Dakota, 2001

Thuy Ha Nguygen, M.D.Oregon Health & Science University, 2001

Carrie A. Lucidi Phillipi, M.D.University of California at Davis, 1999; Ph.D., University of California at San Diego (neurosciences)

Eric Alan Steele, M.D.Baylor College of Medicine, 2001

Second-Year (2001-2004)Christopher Barone, M.D.Albany Medical College, 1999

Sandy Lifan Chen, M.D.University of California at Davis, 2000

Christen K. Richard, M.D.University of North Dakota, 2000

Jonathan Solomon, M.D.Temple University, 2000

Third-Year (2000-2003)Jane Gilbert, M.D.University of Arizona, 1999

Thomas D. Myers, M.D.University of Utah, 1999

Andrew S. Westfall, M.D.Oregon Health & Science University, 1999

CCAASSEEYY’’SS RREESSIIDDEENNCCYY PPRROOGGRRAAMM

Affiliated with the Oregon Health & Science University School of

Medicine and directed by Andreas K. Lauer, M.D., the Casey Eye

Institute’s residency program is one of the most sought-after in the

United States. In 2002 we received more than 300 applications for

four positions starting in July 2004.

One reason for this popularity may be CEI’s high faculty-to-resident

ratio, which affords residents the opportunity to observe many dif-

ferent practice styles and allows a healthy balance between super-

vision and graded responsibility. Casey’s proximity to Devers Eye

Institute and the Portland Veterans Administration Medical Center

(conveniently linked to OHSU Hospital by a skybridge), means

additional clinical and surgical experience for residents; our status

as a “top ten” national research center, with over $10 million per

year in external funding, means an abundance of scientific opportu-

nities. In fact, Casey residents have a dedicated research rotation

during their first year. Our curriculum also includes courses in prac-

tice management designed to help prepare residents for a future in

either academic medicine or private practice.

In our 120,000-square foot, state-of-the art facility, residents receive

excellent training in comprehensive ophthalmology and exposure to

all of the generally recognized ophthalmology subspecialties.

Susan Bony, Residency Program Coordinator

34

C o n t r i b u t i o n s t o C a s e y Ey e I n s t i t u t e i n 2 0 0 2

The faculty and staff of Casey Eye Institute thank the following individuals, foundations, corporations and groups that

made charitable contributions to OHSU Foundation in support of Casey in 2002. Gifts were made for both unrestricted

and restricted purposes. We are grateful for the many and generous gifts we receive, and for those who have included

Casey in their estate plans.

Names followed by an asterisk indicate deceased donors. We have endeavored to make this list as

accurate and complete as possible, but should you find an error, or wish to be listed differently, please let us know.

Anonymous (9)

Bernita Abel

Don E Abraham

Ellen Abraham

Mr & Mrs Tom Accettura

Alice Julia Adams Estate

Marian P Ahlberg

Virginia A Ahrens

Sheldon W Ainslie

Alcon Foundation

Sherry E Allen

Allergan

Mr & Mrs Kermit S Alskog

Dorothy C Ambrose*

Thomas L Ambrose Jr

Bernice E Anderson*

Bonnie B Anderson

Mr & Mrs Elven V Anderson

Mr & Mrs Douglas W Anderson

Mr & Mrs Frederick J Anderson

Mr & Mrs Gordon A Anderson

James C Anderson

Margaret A Anderson

Richard D Anderson

Robert H Anderson

Mr & Mrs William C Anderson

Mr & Mrs Duane Andrews

Androsia International Trade

Captain & Mrs Phillip E Appleton

Mr & Mrs Will B Arndt

Charles A Arnold

Bula Buck Arveson Estate

Mr & Mrs John C Ashton

Jean L Aslakson

Mr & Mrs Ray B Auel

The Autzen Foundation

Aventis Pharmaceuticals Inc

Mr & Mrs Edmund J Aziz

Eleanore P Baccellieri

Annette Backous

Mr & Mrs Victor Backstrom

Mr & Mrs Warren R Bacon

Nadia R Badawi

Mr & Mrs Mark W Bailey

Mr & Mrs Stephen M Bailey

Mr & Mrs Wesley K Bailey

Lorraine H Bajus

Mr & Mrs Benjamin J Baker

Bud Baker

Joanne F Baldasar

Mr & Mrs Bradley C Barclay

Mr & Mrs James E Barnard

Mr & Mrs Eldon H Barnes

Dr & Mrs Richard Barrar

Corleen M Barrett

Mary M Bartholomew

Ronald L Bartlett

Mr & Mrs Benjamin F Barton

Mr & Mrs Thomas W Bartosz

Richard D Bartsch

Mr & Mrs Noble D Bashor

Marie C Bates

Marlys Jean Bauer

Betty J Bauman

Mary L Bauman

Mr & Mrs Harold J Beal

Chester Becker

Erna G Beggs

Mr & Mrs Barry H Belau

Alma J Belenski

Mr & Mrs Matt Benedict

Elizabeth A Bennett

Paul H Benninghoff

Mr & Mrs Elmo S Benton

Mr & Mrs Donald I Berkey

Mr & Mrs George Bernards

Henny Bernstein

Harry L & Renata Berry

Mr & Mrs Mark S Bessette

Leslie Bevan PhD

Claire E Beyer

Mr & Mrs Everett E Bieger Jr

Mary & Brot Bishop

John R Bjoin

Mr & Mrs Norman E Bjorklund

Mr & Mrs Jack L Bjorkman

Mr & Mrs John L Blackwell

David G Blake

Eileen R Blaser

Dorothy L Blattner

Mr & Mrs Keith D Bleich

Margery W Bloomfield

Dr & Mrs Lewis E Blue

Bluebird Properties

Mr & Mrs William H Boatman

Mr & Mrs Gordon E Bock

Mr & Mrs John F Bohler

Mr & Mrs Carl E Bond

Annette R Boslar

Lawrence P Bouchard

Anna Belle Bowen

Sally B Bowerman

John M Boyer DO

Jean Braden

Mr & Mrs John M Bradley

Carol L Brashear

Mr & Mrs Fred J Breidenbach

Jerome B Brem MD

Beth and Chris Brentlinger

Brobeck Phleger & Harrison LLP

Mr & Mrs Murlin J Brock

Patricia G Brodkorb

Ida M Brooks

Mr & Mrs Bobb F Brown

Christopher H Brown

Gordon E Brown

Jean E Brown

Mr & Mrs John H Brunke

Elia J Buckles

Janice I Budworth

Mr & Mrs L L Budzak

William E Burch

Ella Munro Burdin Fund at

Oregon Community Foundation

Elizabeth A Burgess

Mr & Mrs Robert C Burgess

Mr & Mrs Kenneth E Burgus

Gretchen A Burk

Mr & Mrs Randal T Burk

Thomas Burk Jr

Dorothea L Burke

Mr & Mrs Thomas C Burnard

Ruth K Burns

Robert E Bush

Michael E Butry

Mr & Mrs Donald M Cades

Cahn Family Trust

Mr & Mrs Marvin S Cahn

Dr & Mrs Douglas T Campbell

Mr & Mrs John A Campbell

Mr & Mrs Raymond U Cappelli

Mr & Mrs Billy D Carder

Mr & Mrs Milton Carl

Mr & Mrs Claude W Carlile

Douglas M Carney MD

Frank P Carraher

Brent R Carreau

John A & Helen M Cartales

Foundation

Mr & Mrs Rodney B Carter

The Annie E Casey Foundation

Myrna A Casono MD

George H Caspar MD

Mr & Mrs Ted W Cauthorn

Susie M Cawley

Mr & Mrs Leonard L Cebula

Mr & Mrs William H Chaffee

Alan L Chaimov MD

Mr & Mrs Vutha Chau

Alyce R Cheatham

Mr & Mrs J M Checkoway

Mr & Mrs John D Chenoweth

Evelyn Christensen

Laurie E Christensen MD

Kelly D Chung MD

Mr & Mrs Michael Clarenbach

Clarendon National Insurance

Company

Clark Foundation

George L Clark

James B Clark

Mr & Mrs Jerry J Clark

35

Leona M Clark

Mrs Mary Clark

Maurie D Clark*

Mr & Mrs Mike Clark

Mr & Mrs W Lewis Clark

Nancy L Clary

Mr & Mrs Patrick J Clary

Mr & Mrs Judson B Clifton

Darin B Closson OD

Mr & Mrs Donald A Cobert

Dr & Mrs William Cohen

Hilda Cohrs

Jesse L Colbert

Mr & Mrs Albert D Cole

Ethel L Cole

Doris H Coles

Vicki L Coles

Collins Medical Trust

D J Collins

Judy M Collins

Maribeth W Collins

Gerald V Colombo

Joyce F Colwell

Community Bargain Counter

Community Health Charities

Mr & Mrs Randy Compton

Consolidated Auto Works

Mr & Mrs John A Conway

William V Cook

Mr & Mrs William N Cooper

Albert S Copeland

Ruth Copenhagen

Barbara J Cordill

Wade W Cornwell

Lionel Correia

Elizabeth D Cottle

Mr & Mrs John A Courtney

Mr & Mrs Donald G Cowgill

Mr & Mrs William F Cowning

Janice Cramer

Loy E Cramer MD

Jennie M Crane

William C Crane

Janet L Crawford

Crestwood Construction

Edward L Crockett

Edith B Cross

Rosemary Crowder

Bernice Crump

Mr & Mrs Carl L Cunningham

Margaret M Curran

Current/Paper Direct

Irja V Curtis

Helen F Cushing

Charles J Custer

Mr & Mrs W G Custer

Ellen B Dagan

Raymond H Dahl

Mr & Mrs A Dennis Dahlin

Betsy W Dailey

Roger A Dailey MD

Barbara Dalman

Maude Daniels

Stanley E Danill

Patricia A Darby

Beatrice Darlington

Evan T Davies

Mr & Mrs N D Davis

Mr & Mrs James E Davis

Mr & Mrs Mark D Davis

Marvel D Davis

Mr & Mrs Ralph M Davis

Mary A De Witt Smith MD

Beverly DeAngelo

George R Dederyan

Robert DeGallery

Richard & Mary Deich

Dr & Mrs James Rodney Delp

Mr & Mrs Thomas P Delsman

Ruth M Demers

Hattie A Dennis

Janet L Dennis

Mr & Mrs John E Depweg

Elizabeth Descamps

Desert Camera Club

Desert Grove Mobile Estates

David Dethlefsen

Donald Dickey

Marjorie Dickman

William C Dietz DMD

E Jean Dillard

Gail W Dils

Tuan Anh Do

Rachel Dohanian

Viola A Donahue

John Dooley

Mr & Mrs Donald D Doran

Mr & Mrs Benjamin Dortch

DPR Construction

Aileen M Duckwall

Mr & Mrs Maurice L Dufault

Mr & Mrs Dominic A Dulcich

Dr & Mrs David G Duncan

Mr & Mrs John H Dunkak

Donald A Durand

Fern Durbin

Fred W Durbin

Mr & Mrs Clark Duvall

Mr & Mrs Craig R Duvall

Joanne L Earle

Emma Early

Colonel & Mrs Frank Easley

Marilyn S Easly

Martha Eaton

Ronald G Ebel MD

Jill Edelson

Richard H Edelson MD

Lynnell Edwards

Pleasant L Edwards

Mr & Mrs Edward C Egan

Robert A Egan MD

Mr & Mrs Merle T Egge

Lester H Eisendorf MD

Sylvia Eisendorf

Robert M Eisinger

Mr & Mrs Jerry L Ekstrom

Janice G Elder

Mr & Mrs Harrison W Elgin Jr

Mr & Mrs James H Elgin

Mr & Mrs Robert C Elgin

Robert Eliason

Elk-On-Wheels Travel Club

Mr & Mrs Harold C Ellicott

Sachiko T Ellis

Ellis-Ranian Travel Inc

H C Enloe

Mr & Mrs Thomas M Ensman

Jean Epstein

Mr & Mrs George E Erickson

Raymond L Erickson MD

Mr & Mrs Charles W Ertelt

Elizabeth C Evans

Mark S Evans

Sandra L Evans

ExxonMobil Foundation

Mr & Mrs Stanley E Farr

William F Farr MD

Jennifer Farrer

Ruth A Fasbinder

John N Fax

Ruby E Fax*

Mr & Mrs George Ferrington

Myra L Ferris

Mr & Mrs Michael A Fiasca

Dolores Fielder

Allen Figone

William S Findlay CLU ChFC

Mr & Mrs Roy E Finley

Rose M Finn

Debbie H Fisher

Mr & Mrs James W Fisher

Fishhawk Fisheries Inc

Mr & Mrs Brian D Fitzgerald

Helen D Fitzgerald

John D Flanagan MD

Mrs Doris M Floura

Helen C Fong

Eunice G Forinash

Hazel Forty

Mr & Mrs Walter W Foster

The Foundation for Fighting

Blindness

Carolyn Fowler

Geoffrey G Fowler

Cluff E Francis*

Irene M Francis

Dr & Mrs Frederick T Fraunfelder

Rick Fraunfelder MD

Percy F Freeman Jr

Mr & Mrs George J Freiberg

Don & Emilie Frisbee

Shirley P Frisz

Mr & Mrs John N Fullenwider

Mr & Mrs Oliver H Funk Jr

Lloyd M Gabriel

Wayne L Gannon

Gap Foundation Gap Giving

Program

Mr & Mrs Burton S Garbow

Melvin C Garbow

Mr & Mrs Pat E Garcia

Rachael L Garrett OD

Goldie Gaska

Mr & Mrs J Peter Gaskins

Mr & Mrs Daniel K Gassner

Devin M Gattey MD

Marcile M Gatzke

Janet Gefre

Mr & Mrs Charles T Geldaker

Carolyn S Gentry

Mr & Mrs Theodore Gerson

Mr & Mrs Richard J Gibler

William J Gibler

Evelyn E Gieszler

Mr & Mrs Dale Gilkison

Mr & Mrs R A Girton

Shirley Gittelsohn

Mr & Mrs Vernon D Gleaves

Antonio J Glokner

Arlene W Glueck

Helen Goffin

Mr & Mrs M M Goldhamer

Norma J Goldsby

Mr & Mrs Jay Goldstein

George & Carolyn Goodall

Foundation

36

C o n t r i b u t i o n s t o C a s e y Ey e I n s t i t u t e i n 2 0 0 2

Mr & Mrs Robert L Goodman

Shawn Goodman MD

Mr & Mrs Tom Gordon

Sarah L Gore

LaVerda J Goudge

Dr & Mrs Jack A Gow

Ruth A Grady

Mr & Mrs Leal W Graham

Mr & Mrs Thomas M Graham

Mr & Mrs Elden R Gray

Victor R Greb

Mr & Mrs Lester D Green

Mr & Mrs Ronald W Griffin

Eileen A Grigsby

Mr & Mrs Howard A Grimes

Mr & Mrs Cal R Grimmer

Mr & Mrs Robert S Grove

Stanley Gruszka

Maruth G Gruver

Mr & Mrs Anthony J Gubanc

Gerry R Guest

Sandra G Guilfoil

GVNW Consulting Inc

Mardell M Gwinn

Bette B Hagman

Stephanie A Hahn

Mr & Mrs Brian S Hair

Mary A Haisch

Guinivere B Hall

Mr & Mrs Kirby Hall

Charlotte Hallowell

Mr & Mrs Raymond W Haman

Mr & Mrs Timothy Hamilton

Mr & Mrs Michael Hammack

Mr & Mrs J C Hammond

Mr & Mrs Robert H Hango

Michael C Hankins

Joseph J Hanna Jr

Arthur Hansen

Betty Q Hansen

Jean C Hansen

Mr & Mrs Donald O Hanson

Lumier E Hanzel MD

Mr & Mrs Cleo A Harding

Mr & Mrs James A Harper

Sherris Harrell

Bertha L Harris

Diane Harris

Mr & Mrs Wayne O Harris

C Allan Hart Estate

Marilyn A Hart

Davis A Harvey Estate

Mr & Mrs Kirby B Haskell

Milton Hasson DMD

Dorothy I Hay

Mr & Mrs Gary M Haynes

Mr & Mrs Harry E Hearn

Mr & Mrs Dan Heimbuck

Mr & Mrs Joseph L Heinz

Mr & Mrs Eugene H Helgerson

Marion Hembling

Alexander Henderson Insurance

Services

Mr & Mrs Roger B Henderson

Margaret M Hendricks

Emma B Henell

Margaret W Henzi

Josephine V Herman

Mr & Mrs Bertram J Hermens

Kathryn A Hibbard

Mr & Mrs Jim Hibbert

Mr & Mrs Howard R Hickam

Richard A Hiersche

Dorothy Hiley

Erland V Hill

Mr & Mrs Jeffrey A Hill

Frederick A Hirsch

Mr & Mrs Harry K Hoard

Mr & Mrs Philip M Hoefer

Mr & Mrs Charles Hoehner

Michael G Holmes

Margaret W Honeyman

Mr & Mrs Andrew J Honzel

Hooper Holmes

J A Houghton

Mr & Mrs Raymond M Hovee

Mr & Mrs Robert W Howe

Mr & Mrs Howard L Hubbard

Harry E Hudson*

Mary S Hudson

Mr & Mrs Michael B Huffman

Mr & Mrs Dave Huffstutter

Louise Hults

Mr & Mrs Kenneth C Hume

Robert L Hurst

Muriel Hyman

Mr & Mrs John R Hyslop

The IFC Foundation

Edgar F Imle

Mr & Mrs John J Inskeep

Jo Ann Jacobsen

Robert P Jacobsen Jr

Thelma M Jacobsen

Benjamin G Jacobson

John Jaksic

Mr & Mrs George James

Mr & Mrs Don G Jefferys

Kelley S Jensen

Val & Mary Ellen Jensen

Bonnie R Jepsen

Irene Jessen

Mr & Mrs Henry N Jinings

V Carol Johns

Mr & Mrs Dale E Johnson

David S Johnson

Gloria A Johnson

Mr & Mrs Marvin L Johnson

Roger J Johnson

Mr & Mrs Stanley B Johnson

Mr & Mrs Weston W Johnson

Jack F Johnston Jr

Evelyn L Jones Estate

Edeltrude Jones

Dr & Mrs Richard T Jones

Mr & Mrs Michael R Jordan

Harry S Joseph

Mr & Mrs Thomas R Joste

Frances W Jubitz

Marcia Kahn MD & Howard S

Rosenbaum MD

Kaiser Permanente

Mr & Mrs Calvin L Kaser

Mr & Mrs Richard Kathrens

Ethel K Katz

Margaret Kearney

Lewis G Kearns

Mr & Mrs George E Keep

Keller Foundation

Esther G Kelley

Mr & Mrs Cyrus H Kelly

Fern A Kelly

Mr & Mrs Robert V Kelly

Tamara L Kelly

Judith L Kennedy

Louis J Kennedy

Grace Kent

Mr & Mrs Oscar F Kern

Mr & Mrs Donald E Kernutt

Samuel R Kerr

Mr & Mrs Charles L Kibby

John B Kiefer

Heather K Killough

Mr & Mrs Robert L Kimmel

Mr & Mrs Eugene C Kinder

Mr & Mrs Allen R King

Mr & Mrs Keith R Kingsley

Barbara Kirkhart

Audrey & Joe Kirshenbaum

Donor-Advised Fund

Stephen M Kiser

Mr & Mrs Kenneth S Klarquist

Michael L Klein MD

Mr & Mrs Robert Klein

Fran Knapp

Pamela K Kniffin

Karen Knippling

Robert Knockaert Jr

Edith E Knouff

Harley Koch

Karen G Koch

Richard W Kohl

Mr & Mrs August Kollom

Mr & Mrs William C Kolzow

Mr & Mrs Joseph E Kordic

Kay E Kowitt

Mr & Mrs Sanford Kowitt

Lloyd B Kozera*

Mr & Mrs Herman E Kraft

Mr & Mrs Calvin Krahmer

Donald L Krahmer Sr

Mr & Mrs Gary F Krahmer

Mr & Mrs Steven W Krake

Claudine Kratzberg

Mr & Mrs Fred N Krecklow

Tammie Krisciunas OD

Mr & Mrs Keith Kruchek

Mr & Mrs Kenneth R Kruger

Susan Kuckenberg

Hilda Kullberg

Robert W Kullberg MD*

Mr & Mrs Vincent E Kurpan

Mr & Mrs Howard D Kyle

RoJene LaBarbera

Lachenmeier Enloe & Rall

Dorothy E Lakaff

Edward P LaKaff*

Mr & Mrs Richard E Lakeman

Mr & Mrs Ronald E Lambert

Anthony Landriscina

Mr & Mrs Donald H Landwehr

37

Frank V Langfitt III

Frank V Langfitt Jr

Violet L Langfitt*

Cynthia A Larsen

Mr & Mrs J Brad Larsen

Mr & Mrs Len R Larson

Eileen M Lassiter

Andreas Lauer MD

Mr & Mrs E E Lavier Jr

Mr & Mrs C Rex Layton

Annie Leap

Ruth C Lear

Robert O Lee Estate

Susan L Lehr

Mr & Mrs James H Leiper

David A Leith

Lematta Foundation

Herman Lenz

Mr & Mrs Noel A Lesley

Betty B Leuthold

Richard Lee Levy Estate

Violet Lewis Living Trust

Anita J Lewis

Max E Lewis

Eleanor L Liefke

Judith C Lillestol

Joanne M Lilley

Mr & Mrs Willis Lilliquist

Mr & Mrs Robert M Lindahl

Eva V Lindsay

Mr & Mrs Robert D Lindsey

Mr & Mrs Edward S Lohr

Mr & Mrs Howard W Long

Karen M Lotz

Mr & Mrs A S Lough

Mr & Mrs E Russell Love

Mr & Mrs Richard S Love

Marlene A Lowe

Mr & Mrs Robert R Lowry

Mr & Mrs Fred Lukasavage

Mr & Mrs Scott B Lukins

Mr & Mrs Christopher A Lulay

Kenneth A Lundeberg MD

Lt Col & Mrs Stanley R Luther

Mr & Mrs James J Lydon

Mr & Mrs Myron H Maas

Damien C Macaluso MD

Elizabeth A Macaulay

Maybelle Clark Macdonald Fund

Mr & Mrs Ian Mackenzie

Enid J Mackin

Mr & Mrs Haakon T Magnussen

Jack Majors

Thalia Malone Estate

Helen G Marks

Mr & Mrs Dale J Marshall

Arleen A Martin

Robert A Martin

Gwendolyn S Mason

Mr & Mrs Donald E Mast

Phyllis Master-Cohen

William D Mathers MD

Mr & Mrs Leslie E Matson Jr

Phyllis J May

Mayfair School Sunshine Club

Mr & Mrs Elmer C Mays

Mr & Mrs C W McBride

Mr & Mrs Blair D McCabe

Edmund B McCall

Andrew J McCann PE

Mr & Mrs John S McCormac

Ms Elizabeth T McCoy & Mrs

Anne McCoy

Kay McCoy

Mr & Mrs John M McCullen

Mr & Mrs Marvin G McEldowney

James C McFarland

Mr & Mrs Robert L McFarlane

Mr & Mrs J R McGinnis Jr

Mr & Mrs Paul E McGovney

Mr & Mrs W S McGuire

Mr & Mrs George I McInroy

Mr & Mrs Donald H McIntyre

Jessie E McKenzie

Mark McKinney

Mr & Mrs Paul F McMahon

Claudia Lacey McNeil

Mary C McNulty

Ferne C McPhee

Susan I Means & Gene R

Osborne

Gilbert Meigs

Mr & Mrs George H Meistrell

Mr & Mrs Frank A Mena Jr

Merck & Company Inc

Merck Company Foundation

Mr & Mrs Dotson T Merritt

Mr & Mrs Matthias H Mesdag

Joann M Metcalf

Metropolitan Pediatrics LLC

Mr & Mrs James T Meyer

Mr & Mrs Donald G Meyers

Mr & Mrs Stanley Michalek

Miix Insurance Company

Delia E Miller

Mr & Mrs Richard G Miller

Mr & Mrs Steven C Miller

Vera Miller

Virginia A Millerup

Eugene C Mintkeski

Paul S Minty

Farhad Mirhady PhD

Nancy L Mitchell

Rose Mitchell

Mr & Mrs Richard Miyahira

Patricia L Mobley

Barbara Modey

Mr & Mrs Zoltan Mokrai

Mr & Mrs Gerald L Mongillo

Irvin W Monk

Mr & Mrs Alexander S Moore

Mr & Mrs Darmond L Moore

Jack L Moore

Mr & Mrs Jerome A Moore

Mr & Mrs Richard B Moore

Mary W Moreland

Dolores D Morelli

Patrick Morgan

Mr & Mrs V H Morgan

Dorothy N Morrison

John C Morrison MD

Lynne H Morrison MD

Mr & Mrs Todd H Morrison

Paula T Morrow

Jean Morse

Christopher R Moser

Mr & Mrs Kenneth A Moss

Mr & Mrs R S Moss

Patricia Mueller*

Robert L Mueller MD

Evelyn V Mullin

Mr & Mrs David M Munro

Patra Murdock

Francis S Murphy

Mr & Mrs John W Murphy

Mr & Mrs Tim R Murphy

Helen E Murray

Mr & Mrs Robert J Murray

Mr & Mrs Louis Nadell

Bernard H Naftalin

Doris S Naudain

John T Naylor*

John V Naylor

Ruth T Naylor

Diana L Nead

Mr & Mrs Clyde W Needham

Terrence P Neiman

Dorothy F Nelsen

Mr & Mrs B T Nelson

Ruth Nero

Mr & Mrs Wilfred N Neth

Frank L Newell

Enid Newman

Sandra W Newton

John D Ng MD

Mr & Mrs Jim Nicolaisen

Mr & Mrs Verne A Nielsen

Mr & Mrs Carl A Nolte

Mr & Mrs James E Norem

Sharon L Norene

Mr & Mrs W A North Jr

Mary E Nousanen

Guy Nowels

Mr & Mrs Robert H Noyes Jr

Nu Master Chapter # 440 Beta

Sigma Phi

Susan D Nunn

NW Natural

Kathryn Nyberg

Mr & Mrs Harold Nygaard

Dolores Oaklief

Mr & Mrs Homer E Oblander

Mr & Mrs George Okita

Fumiko Okubo

Mr & Mrs Donald Oldemeyer

Mr & Mrs Michael Z Olds

Mrs Virginia E Oliver

Helen N Olson

Oliver D Olson

Mr & Mrs William F O'Neil

Peter & Claire Opton Fund of the

Oregon Community Foundation

Joecile Orcutt

OHSU Medical Group Inc

Oregon State Elks Association -

Elks Youth Eye Services (EYES)

Oregon State Elks Visual

Program

Raymond O'Reilly

Preston H Orem

Mr & Mrs Laimons Osis

Susan K David Oswald

Mr & Mrs W Scott Overton

Mr & Mrs Alphonse J Pacella

The Honorable Robert W

Packwood

Evelyn J Page

Richard M Page DDS

Earl A Palmer MD

Ruth E Palumbo

Erna Pamer

Pamplin Foundation

Papé Family Foundation

Mr & Mrs Santino Paperini

Dr & Mrs Brent M Parker

Mr & Mrs W L Parker

38

C o n t r i b u t i o n s t o C a s e y Ey e I n s t i t u t e i n 2 0 0 2

Mr & Mrs Bob L Parnell

Mr & Mrs A Donald Parr

Marilyn J Pate

Thomas G Paterson Sr

Mr & Mrs Rolland E Patterson

Karol Peck

Meadow Pederson

Mr & Mrs Morton D Pelzner

Mr & Mrs William Pendarvis

Kathleen E Percell

Mr & Mrs Albert D Perpuse

Chuck Perrott

Vesna Persun

Sally N Peters

Mr & Mrs Douglas L Peterson

Margarett D Peterson

Mr & Mrs Paul L Pettry

Mr & Mrs Jack D Pfeifer

Ruth C Phalen

William H Phalen*

Mr & Mrs Robert W Philip

Margaret F Phillips

Mr & Mrs Michael G Phillips

Wallace W Phillips Jr

Shirley M Pickett

Mr & Mrs Donald C Pierce

Mr & Mrs Charles T Pietrok

Austin M Pitcher

Platt Electric Supply Inc

Sandy & Harvey Platt

Mr & Mrs Wilson G Plummer

Barbara L Poitras

Robert & Barbara Polachek

Deborah T Pollack

Dorothy Pomeroy

Leonard Popick

Mr & Mrs Gerald Poplack

Mr & Mrs Robert E Potter

Doris M Prentice

Mr & Mrs John M Prince

Linda Prinsen

Richard Pryne

Mr & Mrs David L Prysock

Donald E Pullen

Ernestine H Pullen*

Lorraine & Bill Purnell

Roger Pye

Mr & Mrs John F Pynes

Mr & Mrs Bill F Racine

Norma Ragsdale

Nicholas L Rains

Joan A Randall

Joan L Ratliff

Margaret Rawlinson

Robert P Ray

Louvera H Raymond

Mr & Mrs William Reade

Mr & Mrs William L Reagan

Martin W Reeves

Mr & Mrs Douglas S Rehwoldt

Mr & Mrs John W Reiley

Richard G Reiten

Allen Reiter

Laura M Reith

Gertrude F Rempfer

Mr & Mrs William T Rennie

Research to Prevent Blindness

Yancey Reser

Jean S Reynolds

Margaret D Rhodes

Larry F Rich MD

Michael E Richl

Mr & Mrs David Richlen

Robert & Marilyn Ridgley

Charitable Gift

Fund of FICGF

Hugh B Riley

Mr & Mrs James F Rippey

Mr & Mrs Donald J Rischard

Greg P Rivelli

Mr & Mrs George D Rives

Mr & Mrs Irvine Robbins

Mr & Mrs John E Roberts

Harold L Robertson

Mr & Mrs Joseph E Robertson Sr

Joseph E Robertson Jr MD

Mr & Mrs Wayne M Robertson

Amy Joyce Robinson

Anne E Robinson

Mr & Mrs Philip J Robinson

Hazel L Robitsch

Susan G Roeger

J L Rogers

Joan F Rolling

Mr & Mrs Guy H Rooth

Mr & Mrs Sidney L Rosen

Edward E Rosenbaum MD

Howard S Rosenbaum MD

Dr James T Rosenbaum &

Dr Sandra J Lewis

Joan G Rosenbaum

Robert A Rosenbaum MD

Thomas J Rosenbaum MD

Stanley & Madelle Rosenfeld

Fund of Oregon Jewish

Community Foundation

Mr & Mrs Mark H Rosenthal

Brenda Lynn Ross Vision Fund of

Oregon Community Foundation

Helen Ross

Thelma M Ross

Editha Rowell

Peter P Rowell MD*

Eileen C Royster

Trelba L Rubenser

Mr & Mrs Randall Rubenstein

Ronald L Rubin

Muriel H Ruble Yandle

Mr & Mrs Roy J Rucker

Mr & Mrs Rollie Ruehlman

Mr & Mrs Alexander Runciman

Geneva Runciman

Rodney Russell

Mr & Mrs Ronald A Russell

Ramona F Russum

Saalfeld Griggs Gorsuch

Alexander & Emerick

Liwanag L & Abundio L Sadang

Salem Cardiology Associates

Salem Hospital Medical Staff

Jack J Saltzman

Marjorie Saltzman

John R Samples MD

Lillian L Sanchietti

William M Sander

Mrs Marie D Sanders

Mr & Mrs Robert C Sanders

Wilbert Sanders*

Mr & Mrs Fred G Sartwell

Donna J Sather

Jeaneatta Sautter

Mr & Mrs James M Sayers

Scharf Properties Ltd

Alberta G Schmidt

Janette L Schneider

Mr & Mrs Robert S Schneider

Mr & Mrs Stanley W Schneider

Leonard Schnitzer DMD

Lois Schnitzer

Shirley M Schriner

Mr & Mrs Gilbert L Schroff

Schwabe Williamson & Wyatt

Agnes E Schwarzin Estate

Mr & Mrs Willard C Schwenn

Linda F Schwerdt

Mr & Mrs Wesley D Scott

Yvonne Scroggins

Mr & Mrs Lee Seeger

Reha P Seekins

Kenneth W Self

Robert K Semans

Lt Col & Mrs Richard W Sexton

Dorothy A Shannon

Sharkey Family Charitable

Foundation

Mr & Mrs John E Shaw Jr

Dr & Mrs Russell D Shelden

Mr & Mrs Robert W Shepard

Thomas Sheppard

Mr & Mrs Charles H Sherwood

Mr & Mrs Yoshiro Shintani

Shook Hardy & Bacon LLP

Mr & Mrs Robert O Shrum

William T Shults MD

Mr & Mrs Sam J Simich

Mr & Mrs Forrest W Simmons

Mr & Mrs Roy M Simmons

Edith Sitzer

Mr & Mrs Hans E Skacel

Mr & Mrs Monroe Sliger

Smith Helms Mulliss & Moore

Barbara A Smith

Catherine A Smith PhD

Cherida Collins Smith

Edward S Smith

Frederic W Smith MD

Lear L Smith

Mr & Mrs Lloyd S Smith

Rena C Snyder

Helen J Sokol

Mr & Mrs Verne R Sowers

Charles J Spady

Gail M Sparks

Mr & Mrs Joe M Sparks

Mr & Mrs Ronald M Speed

Mr & Mrs Ken Speer

M Evalyn Speidel

Mr & Mrs Robert C Spielman

Shirley Spurgeon

Ivy T Stacy

39

James S Stacy*

Mr & Mrs Abraham B Stanton

James Stanton

Mona M Stearns Estate

Mr & Mrs Walter Steinbrenner

Susan Stephan

Edward A Stephens Estate

Andree H Stevens

Mary Hoyt Stevenson Foundation

Anne V Stewart

Jenifer Stewart

Loran L "Stub" Stewart

Mr & Mrs Dale W Stewart

Mr & Mrs Virgil A Stiger

Mr & Mrs David A Stockton

Mr & Mrs Herbert G Stoenner

Betty Stone

Mr & Mrs Richard L Stoner

Myrtha Storm

J William Stortz

Ann U Stout MD

J Timothy Stout MD

Mr & Mrs Sam L Stovall

Suzanne R Strahan

Mr & Mrs Wesley C Strahm

Mr & Mrs Gregory T Straub

Cynthia S Strawn

Faith R Strong

Juanita B Struble

Margaret M Sudduth

Eric B Suhler MD

Scot A Sullivan MD

Mr & Mrs Herbert H Sundby

Sharon A Susanka

David C Sutherland

Dr Kenneth C Swan Fund at

Oregon Community Foundation

Dr & Mrs Kenneth C Swan

Mr & Mrs Barry J Swanson

Mr & Mrs Wallace J Swanson

Swedish Society Linnea

A William Sweet

Virginia Sweetland

Leslie J Swope USA Ret

Darl L Synoground

Margaret J Taft

Mary A Talbott

James A Tammaro MD

Stephen G Tandy

Dr & Mrs Eugene E Taylor

Mr & Mrs John C Taylor Jr

Mr & Mrs Randy L Taylor

S H & A M Tebbets Estate

Margaret E Teufel

Mr & Mrs T H Thomas

Fred P Thompson Jr

Reverend & Mrs James S

Thompson

Kathleen Thompson

Mary E Thompson

Mr & Mrs Michael G Thorne

Mr & Mrs Bill G Thornton

Donald E Thorpe

Lucille E Thronson

Charlotte Thuemmel

Bettymae Todrank

Jacqueline V Tompkins

Rena Tonkin

Mrs Moe M Tonkon Fund at

Oregon Community Foundation

Tooze Duden Creamer Frank &

Hutchison

Theodora M Topp

Mr & Mrs Michael D Towers

Carmelita R Tri

Darlene M Tri

Glenn L Tri

Patricia A Tritz

Louise Tucker

Toshikiyo Uchida DMD*

Muriel K Unkeles

Mr & Mrs Thomas R Uphaus

Barbara Uyesugi

Mr & Mrs George Van Biber

Mr & Mrs L E Van Buskirk

David N Van Camp

Kenneth F Van Duyn

Jane Van Dyke

Mr & Mrs David Vanasche

George N Vigeland Jr MD &

Karen M Vigeland MD

Charles A Viltz

Mr & Mrs Gary C Vogel

Paul R Vogt CPA

Mr & Mrs Phillip F von Feldt

Mr & Mrs James Voytko

Mr & Mrs Robert Wack

Joelle K Waddle

Dennis S Wagner DMD

Karol C Wagner

Dorothy Waite

Mr & Mrs H G Waite

Dr & Mrs James R Waldman

Mary M Walker

William T Walker

Mr & Mrs Dennis H Wallace

Patricia Wallace

Mr & Mrs Henry J Wallaert

Mr & Mrs Irvin H Walsh

Henry Walters

Laura D Wanser Foundation

Edward R Ward

John C Warden

Mr & Mrs Edward J Warmoth

Mrs Bert M Warner

Mr & Mrs David Warner

Mr & Mrs Marion R Warner

Neil O Warner*

Washington County Council

on Aging

Mr & Mrs Glenn W Watkins

Robert Watzke MD

Esther G Wayne

Mr & Mrs Byron W Webb

Teresa M Webb

Rosmary Wegert

Mr & Mrs Irving B Weinstein

LaDona M Welch

Dr & Mrs Richard G Weleber

WELfund Inc

Mr & Mrs Grover Welty

Bettie Wennevold

Rita West

Mr & Mrs Jack A Westing

Mr & Mrs Chris L Wheeler

David Timothy Wheeler MD

Mr & Mrs Eldridge H White

Leal Daly Whittlesey

Mrs Louise C Wicks

Noel F Wicks*

Marta Widman

Barbara J Wilkins

Jane H Wilkins

Cora Wilkinson

Mr & Mrs Gary E Will

Dr & Mrs Elvin T Williams

Mr & Mrs J Robert Williams

Mr & Mrs Raymond C Williams

Mr & Mrs Dain A Wilmarth

David J Wilson MD

Reverend & Mrs Doyle E Wilson

James H Winkler

Jeanne L Winn

Lawrence Winthrop

Dr & Mrs Calvin Wipf

Richard G Wirtz

Mr & Mrs Richard Witzany

Gabriel Wolff

Women of the Moose # 1184

Mr & Mrs Bruce L Wong

Mr & Mrs John S Wood Jr

John W Wood MD

Woodland Park Hospital Auxiliary

Jane K Woodward

M L Wooster

Harriet B Workman

Stephen B Workman

Margaret J Worstell

Donald L Wright

Dorothy R Wright

Kathleen Wrightson

Mr & Mrs Fred D Wristen

William W & Janet E Wyse

Dr & Mrs Kan Yagi

Irene A Yamada

Mr & Mrs Dan Yates

Kenneth G Yee

Juan Young Fund at

Oregon Community Foundation

Janet E Young

Mr & Mrs Roy A Young

Mrs Pearl Yu

Mr & Mrs Jack Zidell

Mr & Mrs Carl W Zikeli

Marvin Zink

Susan L Ziolko

Mr & Mrs Robert E Zuck

Mr & Mrs Gary E Zumwalt

40

C a s e y Ey e I n s t i t u t e R e s o u r c e s a n d R e f e r r a l S e r v i c e s

INFORMATION & COMMUNITY SERVICES503.494.3000

ADMINISTRATION503.494.7890Fax: 503.494.4286

CODING AND COMPLIANCE503.494.6107Fax: 503.494.6864

CONTACT LENS SERVICE503.494.5536Fax: 503.494.5372

COUNSELING/SOCIAL SERVICES

503.494.1618Fax: 503.494.5347

DIAGNOSTIC OPHTHALMIC ECHOGRAPHY

503.494.7693Fax: 503.494.5188

ELECTRORETINOGRAPHYSERVICE

503.494.8386Fax: 503.494.5347

ELKS LIAISON503.494.3557Fax: 503.494.2282

EYE BANK503.413.7523

KENNETH C. SWAN LIBRARY503.494.3380

MACULAR DEGENERATIONCENTER

503.494.3537Fax: 503.494.7233

LOW VISION SERVICE503.494.3098Fax: 503.494.2282

NATIONAL REGISTRY OF DRUGINDUCED OCULAR SIDE EFFECTS

503.494.5686Fax: 503.494.4286

NORTHWEST CENTERFOR EYE ALIGNMENT

503.494.1952Fax: 503.494.5347

OPTICAL SERVICES503.494.3030Fax: 503.494.0588

ORTHOPTICS503.494.4961Fax: 494.5372

PHARMACY503.494.3933Fax: 503.494.0048

PATHOLOGY503.494.7881Fax: 503.494.7233

PHOTOGRAPHY503.494.7693Fax: 494.5188

SURGERY SCHEDULING503.494.3943Fax: 503.494.3349

VISUAL FIELD AND HRT STUDIES503.494.7667Fax: 503.494.3017

WEBSITE: www.ohsucasey.com

This 2002 Casey Eye Institute Annual Report was produced by the Oregon Health & Science Unversity Department of Ophthalmologyat the Casey Eye Institute.

Co-Editors and Writers: Genevieve Long, Ph.D., Nancy Mitchell, B.A., C.O.T., Joan Randall, MPHDesigner: Buck Winston

A special thanks to the Casey Eye Institute Ophthalmic Photography Department.Photographers: Mark Evans, Chris Howell, Peter Steinkamp, Pat Wallace

C A S E Y E Y E I N S T I T U T E3 3 7 5 S . W . T E R W I L L I G E R B L V D . P O R T L A N D , O R E G O N 9 7 2 3 9 - 4 1 9 7